Fusion Polypeptides for Metabolic Disorders - Patent application

Abstract

Provided is a conjugate of a polypeptide comprising a nanobody and FGF21 linked by a polypeptide linker.Further provided is a conjugate of a polypeptide comprising GLP-1, a nanobody and FGF21, each linked by two polypeptide linkers.Also provided is a pharmaceutical composition comprising the same and a method for treating a disease.

Description

[Technical field]

[0001] The present invention relates to polypeptides and methods for their production, pharmaceutical compositions and methods of using such to prevent and / or treat diseases, particularly metabolic diseases. [Background technology]

[0002] Fibroblast growth factor 21 (FGF21), a member of the fibroblast growth factor (FGF) family, is a hormone synthesized in several metabolically active organs and regulates glucose and lipid homeostasis. The biology of FGF21 is inherently complex due to its diverse metabolic functions in multiple target organs. FGF21 has been reported to function in organs such as the liver, adipocytes, pancreas, hypothalamus, and muscle tissue (Fisher FM, Annu Rev Physiol, 2016, 78:223).

[0003] The major bioactive fragment of glucagon-like peptide-1 (GLP-1) is a 30 or 31 amino acid peptide fragment (amino acids 7-36 or 7-37 of GLP-1) that arises by post-translational processing of the proglucagon peptide. The initial GLP-1 product GLP-1 has been shown to stimulate insulin synthesis and secretion and prevent hyperglycemia in diabetes, especially type 2 diabetes. However, endogenous GLP-1 has a half-life of only approximately 2 minutes, which results in fasting plasma levels of GLP-1 of only 0-15 pmol / L.

[0004] Metabolic disorders are commonly associated with insulin resistance, visceral adiposity, atherogenic dyslipidemia, etc., which pose a large and growing public health and clinical challenge worldwide. However, existing treatments for metabolic diseases face problems such as short half-life and / or low efficacy. Summary of the Invention [Problem to be solved by the invention]

[0005] Thus, there is a need for improved therapeutic solutions for treating metabolic diseases. [Means for solving the problem]

[0006] In a first aspect, the disclosure provides a polypeptide that is essentially a fusion polypeptide or protein, comprising two or three functional domains connected via one or two linkers.

[0007] Specifically, from the N-terminal to C-terminal direction, the polypeptide comprises a first fragment and a second fragment, connected via a first linker, the first fragment comprising a Nanobody domain capable of binding to serum albumin (e.g., human serum albumin), and the second fragment comprising a biologically active FGF21 domain.

[0008] As used herein, an FGF21 domain comprises an amino acid sequence having at least 90% sequence identity with SEQ ID NO: 1, while substantially retaining its biological activity. Thus, an FGF21 domain may comprise no more than 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 amino acid residue mutations relative to SEQ ID NO: 1, so long as such mutation-containing FGF21 variants still retain the biological activity of FGF21. As used herein, an amino acid residue mutation may be a substitution, an insertion, or a deletion.

[0009] According to some embodiments of the polypeptide, the FGF21 domain may comprise one or more amino acid residue mutations at positions selected from 121, 168, 171, and 180, respectively, relative to SEQ ID NO: 1. Optionally, the one or more amino acid residue mutations in the FGF21 domain may comprise one, two, three, or four of the following three substitutions: N121Q, M168L, P171G, and A180E.

[0010] According to some embodiments of the polypeptide, the FGF21 domain can comprise all three substitutions of N121Q, M168L and A180E, and the amino acid sequence of the FGF21 domain is set forth in SEQ ID NO:5. Other amino acid residues in the FGF21 domain can be additionally mutated in addition to the three mutations. In certain embodiments, the FGF21 domain further comprises the substitution P171G. According to some embodiments of the polypeptide, the FGF21 domain comprises the amino acid sequence of SEQ ID NO:14.

[0011] According to some embodiments of the polypeptide, the FGF21 domain further comprises a conjugable residue. As used herein, the conjugable residue may optionally be at a position within the C-terminal fragment ranging from position 169 to position 181 relative to SEQ ID NO: 1. According to certain embodiments, the conjugable residue is at a position selected from the group consisting of positions 169, 170, 171, 172, 173, 174, 180, and 181 relative to SEQ ID NO: 1. According to some embodiments of the polypeptide, the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 2-5, 89-91, 14, and 102-105, except for the mutation to a conjugable residue at a position within the C-terminal fragment ranging from position 169 to position 181 relative to SEQ ID NO: 1.

[0012] According to some embodiments of the polypeptide, the FGF21 domain comprises the amino acid sequence of SEQ ID NOs: 6-13, 16-19, and 92.

[0013] According to some embodiments, the polypeptide is conjugated to the functional moiety at a conjugable residue in the second fragment containing the FGF21 domain.

[0014] As used herein, the functional moiety conjugated to the FGF2 domain may optionally include a glycosyl moiety or a synthetic chemical moiety.

[0015] According to some embodiments of the polypeptide, the functional moiety comprises a glycosyl moiety and the conjugable residue can be an introduced residue that is glycosylatable, such as a threonine (T) or asparagine (N) residue. More specifically, the conjugable residue can be an introduced T at position 172 or 173, or an introduced N residue at position 170 or 174, optionally relative to SEQ ID NO: 1. According to some embodiments of the polypeptide, the FGF21 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-19.

[0016] According to some other embodiments of the polypeptide, the functional moiety comprises a synthetic chemical moiety. Thus, the conjugable residue may optionally include an introduced cysteine ​​(C), and the synthetic chemical moiety may comprise the structure *-XYZ. Herein, X, Y, and Z are interconnected via bonds, and the * end of X is connected to a conjugable residue on the polypeptide. X is

[0017] [ka] Y may be

[0018] [ka] Z may be

[0019] [ka] where the α position is linked to the α' position and the β position is linked to the β' position. As used herein, R1 can be hydrogen or -COOH; d can be 1, 2, or 3; a can be 1, 2, or 3; b can be 1, 2, or 3; c can be 1 or 2; d can be 1, 2, or 3; e can be 1, 2, or 3.

[0020] According to some more specific embodiments of the polypeptide, the synthetic chemical moiety has the following structure, also referred to herein as Ac-2XADO-EDA-CO-CH2-*:

[0021] [ka] has.

[0022] Optionally, the introduced cysteine ​​can be at a position selected from the group consisting of 169, 170, 171, 172, 173, 174, 180, and 181, relative to SEQ ID NO: 1. According to certain embodiments, the conjugable residue is at position 171 or 174, relative to SEQ ID NO: 1. According to some of these embodiments of the polypeptide, the FGF21 domain comprises the amino acid sequence of SEQ ID NOs: 6-13 and 92.

[0023] In some embodiments of the polypeptide, the FGF21 domain has the following structure:

[0024] [ka] (also referred to herein as Ac-2XADO-EDA-CO-CH2*) conjugated to an introduced cysteine ​​residue in a synthetic chemical moiety having the amino acid sequence of SEQ ID NO:8 with an introduced cysteine ​​at position 171.

[0025] In some embodiments of the polypeptide, the FGF21 domain has the following structure:

[0026] [ka] (also referred to herein as Ac-2XADO-EDA-CO-CH2*) conjugated to an introduced cysteine ​​residue in a synthetic chemical moiety having the amino acid sequence of SEQ ID NO:92 with an introduced cysteine ​​at position 174.

[0027] Other embodiments of the polypeptide alternatively comprise: i) the FGF21 domain comprises the amino acid sequence of SEQ ID NO:6, with the introduced cysteine ​​at position 169; ii) the FGF21 domain comprises the amino acid sequence of SEQ ID NO:7, with the introduced cysteine ​​at position 170; iii) the FGF21 domain comprises the amino acid sequence of SEQ ID NO:8, with the introduced cysteine ​​at position 171; iv) the FGF21 domain comprises the amino acid sequence of SEQ ID NO:9, with the introduced cysteine ​​at position 172; v) the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 10, with the introduced cysteine ​​at position 173; vi) the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 11, with the introduced cysteine ​​at position 174; vii) the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 12, with the introduced cysteine ​​at position 180; or viii) the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 13, wherein the introduced cysteine ​​is at position 181; ix) the FGF21 domain comprises the amino acid sequence of SEQ ID NO: 92, wherein the introduced cysteine ​​is at position 174; and may comprise the following structure:

[0028] [ka] (also referred to herein as Ac-2XADO-EDA-CO-CH2*) is optionally conjugated at an introduced cysteine ​​residue.

[0029] Additionally and alternatively, in some other embodiments of the polypeptide, the FGF21 domain further comprises a P171G substitution relative to SEQ ID NO: 1. In such embodiments, the FGF21 domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 14 and 92.

[0030] In any of the above embodiments of the polypeptide, the Nanobody domain may optionally comprise a VHH domain, which may optionally bind to human serum albumin (HSA).

[0031] Further optionally, the VHH domain may be humanized.

[0032] According to some embodiments, the VHH domain may comprise a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2) and a complementarity determining region 3 (CDR3). Herein, CDR1 may comprise the sequence of SEQ ID NO: 20, or a variant thereof with up to 3, 2 or 1 amino acid mutations; CDR2 may comprise the sequence of SEQ ID NO: 21, or a variant thereof with up to 3, 2 or 1 amino acid mutations; and / or CDR3 may comprise the sequence of SEQ ID NO: 22, or a variant thereof with up to 3, 2 or 1 amino acid mutations, and the VHH domain substantially retains binding specificity to serum albumin, optionally to human serum albumin.

[0033] In certain specific embodiments of the polypeptide, the VHH domain comprises a complementarity determining region 1 (CDR1) comprising the sequence of SEQ ID NO: 20, a CDR2 comprising the sequence of SEQ ID NO: 21, and a CDR3 comprising the sequence of SEQ ID NO: 22.

[0034] In certain specific embodiments of the polypeptide, the VHH domain comprises the amino acid sequence of SEQ ID NO:23, or a variant thereof having at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 99%) identity to SEQ ID NO:23, wherein the variant substantially retains binding specificity and / or affinity to serum albumin.

[0035] As used herein, optionally a variant of SEQ ID NO:23 may have up to 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations relative to SEQ ID NO:23.

[0036] In any of the above embodiments, the Nanobody domain may optionally further comprise an N-terminal extension attached to the N-terminus of the VHH domain, which N-terminal extension may optionally comprise an SG, AG, S, or A amino acid residue.

[0037] According to some specific embodiments of the polypeptide, the Nanobody domain comprises an amino acid sequence selected from SEQ ID NOs: 24-27.

[0038] In any of the embodiments of the polypeptides described above, the first linker may have a length of at least four amino acid residues.

[0039] According to some embodiments, the first linker may not include any acidic amino acid residues, more particularly, the first linker may not include any D or E residues.

[0040] Optionally, the first linker may comprise one or more units of a first repeat sequence, and according to some embodiments, the first repeat sequence may consist of at most 4 or 6 types of amino acid residues selected from the group consisting of G, Q, A, P, T, and S.

[0041] According to some specific embodiments of the polypeptide, the first repeat sequence is G f S g (wherein each of f and g is independently an integer selected from 1 to 5), and may comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NO:35 (GAQP), SEQ ID NO:36 (GQAP), SEQ ID NO:37 (GPAQ), SEQ ID NO:38 (GPQA), SEQ ID NO:39 (GSQP), SEQ ID NO:40 (GASP), SEQ ID NO:41 (GPAS), SEQ ID NO:42 (GPSA), SEQ ID NO:43 (GGGS), SEQ ID NO:44 (GSGS), SEQ ID NO:45 (GGGGS), SEQ ID NO:46 (GSAPGSPAGSPTGSAPGSPA), and GS.

[0042] In certain embodiments, the first repeat sequence may have the amino acid sequence set forth in SEQ ID NO: 35 (GAQP), and the number of units may be an integer from 1 to 10.

[0043] According to certain specific embodiments of the polypeptide, the first linker is selected from the group consisting of SEQ ID NO: 35 (GAQP), SEQ ID NO: 49 ((GAQP)2), SEQ ID NO: 50 ((GAQP)5), SEQ ID NO: 51 ((GAQP) 10 ), and SEQ ID NO: 48 (GGGGSGGGS).

[0044] In any of the embodiments of the polypeptide described above, the polypeptide may further comprise a third fragment beyond the N-terminus of the first fragment, the third fragment comprising another functional domain, wherein the first fragment and the third fragment are connected via a second linker.

[0045] In the present specification, another functional domain of the third fragment may optionally include a biologically active protein or a fragment thereof selected from the group consisting of glucagon-like peptide-1 (GLP-1), insulin, leptin, glucagon, gastrin, gastric inhibitory polypeptide (GIP), amylin, calcitonin, cholecystokinin, peptide YY, neuropeptide Y, bone morphogenetic protein-6 (BMP-6), bone morphogenetic protein-9 (BMP-9), oxyntomodulin, oxytocin, glucagon-like peptide-2 (GLP-2), irisin, fibronectin type III domain-containing protein 5 (FNDC5), apelin, adiponectin, Clq and tumor necrosis factor-related protein (CTRP family), resistin, visfatin, omentin, retinol-binding protein-4 (RBP-4), glicentin, angiopoietin, interleukin-22 (IL-22), exendin-4, and growth hormone.

[0046] According to some embodiments of the polypeptide, another functional domain of the third fragment comprises a biologically active peptide of GLP-1 or a fragment thereof and may comprise an amino acid sequence having at least 70% sequence identity to SEQ ID NO:28, while retaining substantial biological activity thereof.

[0047] As used herein, optionally, another functional domain may comprise one or more mutations at positions 8, 22, 26, 34, and 36, or any combination thereof, relative to SEQ ID NO:28.

[0048] According to some embodiments of the polypeptide, the one or more mutations in another functional domain of the third fragment of the polypeptide may include A8G, G22E, K26R, K34R, and R36G, or any combination thereof. According to some embodiments of the polypeptide, the one or more mutations in another functional domain of the third fragment of the polypeptide may include A8G, G22E, and R36G, or any combination thereof.

[0049] According to some specific embodiments of the polypeptide, another functional domain of the third fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:29 and SEQ ID NOs:31-34.

[0050] In any of the above-mentioned embodiments of the polypeptide comprising a first fragment connected to the N-terminus of the first fragment via a second linker.

[0051] In certain embodiments, the second linker may have a length of at least 4 amino acid residues. In certain embodiments, the second linker may have a length of at least 8, 12, 16, or 20 amino acid residues.

[0052] As used herein, the second linker may comprise one or more units of a second repeat sequence, and the second repeat sequence may consist of at most 4 or 6 types of amino acid residues selected from the group consisting of G, Q, A, E, P, T, and S.

[0053] According to some specific embodiments of the polypeptide, the second repeat sequence is G h S i (wherein each of h and i is independently an integer selected from 1 to 5), and may comprise or consist of an amino acid sequence selected from the group consisting of SEQ ID NO:35 (GAQP), SEQ ID NO:55 (GQEP), SEQ ID NO:56 (GEQP), SEQ ID NO:57 (GPQE), SEQ ID NO:58 (GPEQ), SEQ ID NO:59 (GSEP), SEQ ID NO:60 (GESP), SEQ ID NO:61 (GPSE), SEQ ID NO:62 (GPES), SEQ ID NO:36 (GQAP), SEQ ID NO:37 (GPAQ), SEQ ID NO:38 (GPQA), SEQ ID NO:39 (GSQP), SEQ ID NO:40 (GASP), SEQ ID NO:41 (GPAS), SEQ ID NO:42 (GPSA), SEQ ID NO:43 (GGGS), SEQ ID NO:44 (GSGS), SEQ ID NO:45 (GGGGS), SEQ ID NO:46 (GSAPGSPAGSPTGSAPGSPA), and GS.

[0054] Further, according to some embodiments, the second repeat sequence may have the amino acid sequence set forth in SEQ ID NO: 35 (GAQP), and the number of the one or more units may be an integer from 1-15.

[0055] According to certain specific embodiments of the polypeptide, the second linker comprises an amino acid sequence selected from the group consisting of SEQ ID NO:49 ((GAQP)2), SEQ ID NO:50 ((GAQP)5), SEQ ID NO:51 ((GAQP)10), and SEQ ID NO:52 ((GAQP)14), and SEQ ID NO:47 ((GGGGS)4).

[0056] According to certain specific embodiments of the polypeptide consisting of the first and second fragments, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 63-68, 93, 99, 100, 101, and 107. According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 63, 68, and 100, and is conjugated to a synthetic chemical moiety provided herein at an introduced cysteine ​​residue at position 171 relative to SEQ ID NO: 1. According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence of SEQ ID NO: 93, and is conjugated to a synthetic chemical moiety provided herein at an introduced cysteine ​​residue at position 174 relative to SEQ ID NO: 1. According to certain of these specific embodiments of the polypeptide, the synthetic chemical moiety has the following structure:

[0057] [ka] (also referred to herein as Ac-2XADO-EDA-CO-CH2*). According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-67, 93, and 107, and is not conjugated.

[0058] According to certain specific embodiments of the polypeptide consisting of the first, second and third fragments, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 70, 74, 75, 79-83, 85, 94-98 and 108-109. According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 81-83, 85 and 96-97 and is conjugated to a synthetic chemistry moiety provided herein at an introduced cysteine ​​residue at position 171 relative to SEQ ID NO: 1. According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence of SEQ ID NO: 94 and is conjugated to a synthetic chemistry moiety at an introduced cysteine ​​residue at position 174 relative to SEQ ID NO: 1. According to certain of these specific embodiments of the polypeptide, the synthetic chemistry moiety has the following structure:

[0059] [ka] (also referred to herein as Ac-2XADO-EDA-CO-CH2*). According to certain specific embodiments of the polypeptide, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 70, 75, 79-80, 85, 94, 95, 98, and 108-109, and is not conjugated.

[0060] In a second aspect of the present disclosure, a pharmaceutical composition is further provided. The pharmaceutical composition comprises a polypeptide according to any of the embodiments described above and a pharma- ceutically acceptable carrier.

[0061] In a third aspect of the present disclosure, there is also provided a method of preventing or treating a metabolic disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a polypeptide according to any embodiment described above, or a pharmaceutical composition as described above.

[0062] As used herein, a metabolic disorder can be diabetes, obesity, non-alcoholic steatohepatitis (NASH), cardiovascular-like dyslipidemia, atherosclerosis, alcoholic steatohepatitis (ASH), diabetic nephropathy, gestational diabetes, metabolic syndromes such as metabolic syndrome X, non-alcoholic fatty liver disease (NAFLD), end-stage liver disease, hepatic steatosis (fatty liver), cirrhosis, primary biliary cirrhosis (PBC), or severe hypertriglyceridemia (SHTG).

[0063] In a fourth aspect of the disclosure there is further provided a polynucleotide encoding a polypeptide as defined according to any embodiment described above.

[0064] In a fifth aspect of the present disclosure, there is further provided a vector comprising the polynucleotide described above.

[0065] In a sixth aspect of the present disclosure, there is further provided a host cell comprising the vector described above.

[0066] In a seventh aspect of the present disclosure, there is further provided a process for producing the polypeptide described above. The process comprises: S100: Culturing the host cell described above under conditions that allow expression of the polynucleotide defined above, or a precursor thereof that further comprises a removable tag; and S200: Recovering and purifying the polypeptide or its precursor from the host cell Includes.

[0067] According to some embodiments of the process, the polypeptide is conjugated to a functional moiety at a conjugable residue in the second fragment, and the process, after step S200 of recovering and purifying the polypeptide from the host cell, comprises the following steps: S300: Conjugating a functional moiety to a polynucleotide Further includes:

[0068] In some embodiments of the process, the host cell is E. coli, the vector comprises an E. coli compatible vector, and the polypeptide encoded by the polynucleotide in the vector is codon optimized for E. coli expression.

[0069] According to some embodiments of the process, the step S200 of recovering and purifying the polypeptide from the host cell comprises the following substeps: S210: recovering a precursor of the polypeptide; S220: refolding a precursor of the polypeptide; S230: treating the refolded precursor of the polypeptide to remove the tag, thereby obtaining the polypeptide; and S240: Purifying the polypeptide may include.

[0070] According to some embodiments of the polypeptide production process, the process further comprises conjugating the purified polypeptide with a functional moiety. In certain embodiments, the functional moiety to be conjugated to the polypeptide is

[0071] [ka] (Ac-2XADO-EDA-CO-CH2-*). Throughout this disclosure, the articles "a", "an" and "the" are used herein to refer to one or to more than one (i.e., at least one) of the grammatical object of the article. By way of example, "polypeptide" means one polypeptide or more than one polypeptide.

[0072] In all occurrences in this application where there is a series of recited numerical values, it should be understood that any of the recited numerical values ​​may be the upper or lower limit of the numerical range. It should be further understood that the present invention encompasses all such numerical ranges, i.e., ranges having a combination of upper and lower numerical limits, and the numerical values ​​for each of the upper and lower limits may be any numerical value recited herein. Ranges provided herein are understood to include all values ​​within the range. For example, 1-10 is understood to include all values ​​of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, as well as decimal values ​​where appropriate. Similarly, ranges delimited by "at least" are understood to include the lower value provided and all higher numbers.

[0073] As used herein, the terms "approximately," "about," "around," or the like, are understood to include within three standard deviations of the mean or within the standard range of acceptance in a particular technical field. In certain embodiments, about is understood to vary by at most 0.5.

[0074] The term "or" is used inclusively herein to mean, and is used interchangeably with, the term "and / or," unless context clearly indicates otherwise.

[0075] Terms such as "comprise," "comprising," "contain," "containing," or the like, should be construed as open-ended terms (i.e., meaning "including, but not limited to"), unless otherwise noted.

[0076] The term "including" is used herein to mean, and is used interchangeably with, the phrase "including but not limited to." Similarly, "such as" is used herein to mean, and is used interchangeably with, the phrase "such as but not limited to."

[0077] The term "consisting essentially of" implies the exclusion of all, most, or a negligible amount of other elements, or it allows for elements not explicitly recited, but excludes elements found in the prior art or that affect basic or novel properties. When a polypeptide is said to "consist essentially of" an amino acid sequence, this means that the polypeptide consists primarily of the amino acid sequence with at most 10 (e.g., at most 6, 5, 4, 3, 2, or 1) additional amino acid residues at either or both termini of the polypeptide. [Brief description of the drawings]

[0078] [Figure 1A-1B] 1A and 1B illustrate polypeptides according to two different embodiments of the present disclosure. [Figure 2A-2B] 2A and 2B show the in vitro FGF21 activity of molecules MLC#9, MLC#10, MLC#14, control#6, and the reference compound YH-dual. [Figure 3A-3B] 3A and 3B show the efficacy of molecular control #2, control #6, MLC#9, and MLC#10 in reducing body weight (FIG. 3A) and suppressing food intake (FIG. 3B) in DIO rats. [Figure 4A-4L] Figures 4A-L show the efficacy of molecules MLC#9, MLC#14, MLC#16, and MLC#17, and reference compounds semaglutide, YH-dual, and tirzepatide in reducing body weight (Figure 4A), glucose control (Figure 4B), reducing plasma triglyceride (Figure 4C), LDL-C (Figure 4D), total cholesterol (Figure 4E), and ALT (Figure 4F) concentrations, as well as reducing fat weight (Figure 4G) and liver weight (Figure 4H), along with improving hepatic TG (Figure 4I), hepatic TC (Figure 4J), and insulin sensitivity (Figure 4K), and increasing adiponectin levels (Figure 4L) in DIO mice. [Fig. 5A-5M]Figures 5A-5M show the efficacy of various dosages of molecules MLC#14 and MLC#16 compared to reference compounds semaglutide, YH-dual, and tirzepatide in reducing body weight (Figure 5A), glucose control (Figure 5B), reducing plasma triglyceride (Figure 5C), LDL-C (Figure 5D), total cholesterol (Figure 5E), ALT (Figure 5F), and AST (Figure 5G) concentrations, as well as reducing fat weight (Figure 5H) and liver weight (Figure 5I), along with improving hepatic TG (Figure 5J), hepatic TC (Figure 5K), and insulin sensitivity (Figure 5L), and increasing adiponectin levels (Figure 5M) in DIO mice. [Figures 6A-6H] Figures 6A-6H show the efficacy of various dosages of molecules MLC#16, MLC#19, MLC#6, and MLC#23 compared to the reference compound semaglutide in reducing serum triglyceride (Figure 6C), LDL-C (Figure 6D), and total cholesterol (Figure 6E) concentrations in plasma, as well as fat weight (Figure 6F) and liver weight (Figure 6G), along with improving hepatic TG (Figure 6H). [Figure 7] FIG. 7 shows all of the amino acid sequences disclosed in this disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0079] The following description of the invention is intended to merely illustrate various embodiments of the invention. Therefore, the specific modifications discussed should not be interpreted as limitations on the scope of the invention. It is believed that various equivalents, variations, and modifications can be realized without departing from the scope of the invention, and it is understood that such equivalent embodiments should be included herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.

[0080] definition The terms "protein", "peptide" and "polypeptide" are used interchangeably herein and refer to a polymer of amino acid residues linked by covalent bonds, such as peptide bonds. The proteins or polypeptides provided herein can include naturally occurring or non-naturally occurring amino acid residues, or both. The polypeptides, peptides and proteins provided herein can include any suitable length of amino acid residues, for example, at least 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or more amino acid residues in length.

[0081] The term "naturally occurring" amino acid residue, as used herein, refers to an amino acid residue found in a natural protein or peptide, including all of its D and L stereoisomers, if their structure allows for such stereoisomeric forms. Examples of naturally occurring amino acid residues include glycine (Gly or G), alanine (Ala or A), valine (Val or V), leucine (Leu or L), isoleucine (Ile or I), serine (Ser or S), cysteine ​​(Cys or C), threonine (Thr or T), methionine (Met or M), proline (Pro or P), phenylalanine (Phe or F), tyrosine (Tyr or Y), tryptophan (Trp or W), histidine (His or H), lysine (L The D stereoisomers include, but are not limited to, the twenty common amino acids, including D-amino acids, D-aspartic acid (D-aspartic acid or K), arginine (Arg or R), aspartic acid (Asp or D), glutamic acid (Glu or E), asparagine (Asn or N), and glutamine (Gln or Q), as well as naturally occurring analogs thereof, such as canavanine, pyrrolysine (PYL), selenocysteine, pyrroline-carboxy-lysine (PCL), sarcosine, beta-alanine, phosphoserine, gamma-carboxyglutamic acid, and ornithine. Examples of naturally occurring amino acid residues in their D stereoisomers include, for example, D-aspartic acid, D-serine, D-cysteine, D-alanine, D-glutamic acid, and the like.

[0082] An "amino acid analog" is a compound that has the same basic chemical structure as a naturally occurring amino acid, i.e., a carbon bonded to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methylsulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but will retain the same basic chemical structure as a naturally occurring amino acid.

[0083] As used herein, "unnatural" amino acid residue refers to any amino acid residue not found in nature, including, but not limited to, modified amino acid residues and / or amino acid mimetics that are not one of the known naturally occurring amino acids but function in a manner similar to naturally occurring amino acids. Modified amino acids or mimetics can be created by adding chemical entities such as carbohydrate groups, phosphate groups, farnesyl groups, isofarmesyl groups, fatty acid groups, linkers for conjugation, functionalization, or other modifications. Unnatural amino acids can also refer to amino acids produced by chemical synthesis. Exemplary unnatural amino acids are 2-aminoisobutyric acid (Aib), imidazole-4-acetate (IA), imidazolepropionic acid (IPA), a-aminobutyric acid (Abu), tert-butylglycine (Tle), 3-aminomethylbenzoic acid, anthranilic acid, des-amino-histidine (abbreviated as DesaminoHis, alternatively named imidazopropionic acid, abbreviated as lmpr), beta analogs of amino acids such as β-alanine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, Nα-acetyl-histidine, α-fluoro-methyl- Examples of such amino acids include, but are not limited to, histidine, α-methyl-histidine, α,α-dimethyl-glutamic acid, m-CF3-phenylalanine, α,β-diaminopropionic acid (abbreviated as Dap), 3-pyridylalanine, 2-pyridylalanine or 4-pyridylalanine, (1-aminocyclopropyl)carboxylic acid, (1-aminocyclobutyl)-carboxylic acid, (1-aminocyclopentyl)carboxylic acid, (1-aminocyclohexyl)carboxylic acid, (1-aminocycloheptyl)carboxylic acid, and (1-aminocyclooctyl)carboxylic acid.Introduction of unnatural amino acids into fusion polypeptides, polypeptide fragments, and / or polypeptide complexes can be accomplished by techniques described in Wang et al., Science 292:498-500, 2001; Deiters et al., J Am Chem Soc 125:11782-11783, 2003; Wang and Schultz, Science 301:964-967, 2003; Zhang et al., Science 303:371-373, 2004, or U.S. Patent No. 7,083,970. Briefly, some of these expression systems involve site-directed mutagenesis to introduce stop codons, such as amber (UAG), ochre (UAA), and opal (UGA) codons, into an open reading frame encoding a fusion polypeptide of the present disclosure. Other codons, such as four-base codons (e.g., AGGA, AGGU, CGGU, CGCU, CGAU, CCCU, CUCU, CUAU, and GGGU), five-base codons, six-base codons, etc., can also be introduced into expression systems for unnatural amino acids. Such expression vectors are then introduced into a host that can utilize a tRNA specific for the introduced stop or other codon and carrying the unnatural amino acid of choice.

[0084] The terms "fusion" or "fused," when used in reference to amino acid sequences (e.g., peptides, polypeptides, or proteins), refer to the combination of two or more amino acid sequences into a single amino acid sequence that does not occur in nature, e.g., by chemical linkage or recombinant means. A fused amino acid sequence can be produced by genetic recombination of two encoding polynucleotide sequences and can be expressed by methods of introducing a construct containing the recombinant polynucleotide into a host cell.

[0085] "Percent sequence identity" is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to the amino acid (or nucleic acid) residues in a reference sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum number of identical amino acids (or nucleic acids). In other words, the percent sequence identity of an amino acid sequence (or nucleic acid sequence) can be calculated by dividing the number of identical amino acid residues (or bases) relative to the reference sequence to which it is compared by the total number of amino acid residues (or bases) in the candidate sequence or in the reference sequence, whichever is shorter. Conservative substitutions of amino acid residues are not considered to be identical residues. Alignment for purposes of determining percent amino acid (or nucleic acid) sequence identity can be accomplished using publicly available tools such as, for example, BLASTN, BLASTp (available at the National Center for Biotechnology Information (NCBI) website, see also Altschul SF et al, J. Mol. Biol., 215:403-410 (1990); Stephen F. et al, Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 (available at the European Bioinformatics Institute website, see also Higgins D Get al, Methods in Enzymology, 266:383-402 (1996); Larkin MA et al, Bioinformatics (Oxford, England), 23(21):2947-8 (2007)), and ALIGN or Megalign (DNASTAR) software. One skilled in the art may use the default parameters provided by the tool or may customize the parameters as needed for the alignment, for example by selecting an appropriate algorithm.

[0086] In one embodiment, the present disclosure provides a polypeptide that is essentially a fusion polypeptide / protein that comprises two or three functional domains, and any two adjacent functional domains are operably connected via a linker. Optionally, the fusion polypeptide / protein can be conjugated.

[0087] Figures 1A and 1B illustrate two main embodiments of the polypeptides provided in the present disclosure. As shown in Figure 1A, the first embodiment of the polypeptide 001A comprises a first fragment 100 and a second fragment 200, connected in an N-terminal to C-terminal direction via a first linker 10. The first fragment 100 substantially comprises a nanobody domain capable of binding to serum albumin, such as human serum albumin (HSA). The second fragment 200 comprises a biologically active FGF21 domain that substantially comprises a functional form of FGF21, and according to certain specific embodiments of the present disclosure, comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1, while substantially retaining its biological activity.

[0088] Optionally, the polypeptide may further comprise one additional functional domain in addition to the nanobody domain in the first fragment 100 and the FGF21 domain in the second fragment 200. As shown in FIG. 1B, in addition to the first fragment 100 and the second fragment 200 in the first embodiment illustrated in FIG. 1A, this second embodiment of the polypeptide 001B further comprises a third fragment 300 beyond the N-terminus of the first fragment 100. The third fragment 300 comprises an additional functional domain that may exert a biological activity that is additive or synergistic with the FGF21 domain in the second fragment 200. The first fragment 100 and the third fragment 300 are connected via a second linker 20. According to some embodiments of the present disclosure, this additional functional domain in the third fragment 300 is a biologically active GLP-1 domain that substantially comprises a functional form of GLP-1. According to some embodiments, it comprises an amino acid sequence having at least 70% sequence identity to SEQ ID NO:28, while substantially retaining its biological activity.

[0089] The term "functional form" as used herein refers to various forms of a parent molecule (such as variants, fragments / portions, fusions, derivatives, and mimetics) that, despite having differences in amino acid sequence or chemical structure, still retain substantial biological activity of the parent molecule. As used herein, the phrase "retain substantial biological activity" means exhibiting at least a portion (e.g., at least no less than about 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) or all of the biological activity of the parent molecule. Functional forms of a parent polypeptide can include both naturally occurring variant forms and non-naturally occurring forms, such as those obtained by recombinant methods or chemical synthesis. Functional forms can contain non-natural amino acid residues.

[0090] The term "variant" as used herein refers to a polypeptide that has at least 70% sequence identity with a parent polypeptide and retains at least partial function of the parent polypeptide. A variant may differ from a parent polypeptide by one or more amino acid residues. For example, a variant may have substitution, addition, deletion, insertion, or truncation of one or more amino acid residues of the parent polypeptide.

[0091] The term "fragment" or "portion" as used herein refers to a subsequence of a parent polypeptide of any length. A fragment may still retain at least partial function of the parent polypeptide.

[0092] The term "derivative" as used herein refers to a chemically modified polypeptide or fusion polypeptide in which one or more clearly defined substituents are covalently attached to one or more specific amino acid residues of the polypeptide or fusion polypeptide. Exemplary chemical modifications may be, for example, alkylation, acylation, esterification, amidation, phosphorylation, glycosylation, labeling, methylation of one or more amino acids, or conjugation with one or more moieties.

[0093] The term "mimetic" as used herein refers to a molecular structure that serves as a substitute for an amino acid, peptide, polypeptide, or fusion polypeptide.For example, an amino acid mimic as used herein may or may not be an amino acid, but may be a synthetic structure (known or unknown) that retains the functional properties of the parent amino acid, while the structure of the amino acid mimic is different from the structure of the parent amino acid.Examples include amides, methacryloyl or acryloyl derivatives of β-, γ-, δ-imino acids (such as piperidine-4-carboxylic acid), and the like.

[0094] FGF21 Domain The polypeptides disclosed herein include an FGF21 domain. For example, each of the first and second embodiments of the polypeptides disclosed herein and illustrated in Figures 1A and 1B includes an FGF21 domain.

[0095] The term "FGF21" as used herein refers to and is an abbreviation of "fibroblast growth factor 21" and is intended to broadly encompass native human FGF21 as well as all functional forms thereof, including functional variants, fragments, fusions, derivatives, or mimetics. Native human FGF21 consists of 209 amino acid residues, with amino acid residues 1-28 being a signal polypeptide and amino acid residues 29-209 being a mature polypeptide of 181 residues (Uniprot database with accession number Q9NSA1). The phrase "biologically active FGF21 domain" provided in this disclosure refers to a functional form of FGF21, which may be the mature polypeptide or a functional variant, fragment, fusion, derivative, or mimetic thereof. The mature polypeptide of human FGF21 is included herein as SEQ ID NO: 1. As used herein, the numbering of residues in FGF21 refers to the sequence of SEQ ID NO: 1 beginning with His at position 1 and Ser at position 181.

[0096] The functional form of the mature polypeptide of FGF21 can activate the FGF21 receptor at a level comparable to or at least about 20% (or at least 30%, 40%, 50%, 60%, 70%, 80%, 90%) of that of the mature polypeptide of native human FGF21. Activation of the FGF21 receptor can lead to biological activities such as the ability to activate glucose uptake in adipocytes, the ability to lower blood glucose and triglyceride levels, or the ability to lower body weight (Tezze C et al, Front Physiol. 2019, 10:419). Many functional forms of the mature polypeptide of FGF21 are known, including, but not limited to, WO2019043457A2, WO2018088838A1, WO2018039081A1, WO2017220706A1, WO2017180988A2, WO2017116207A1, WO2017093465, WO2017059371A1, WO2016102562A1, WO2016065326A, WO20131731A1, the disclosures of which are incorporated herein by their entireties. 58A1, WO2013052311A1, WO2013033452A2, WO2012066075A1, WO2012059873A2, WO2012010553A1, WO2011140086A2, WO2010084169A2, WO2010065439A1, WO2008121563A2, WO2006028595A2, WO2006028714A1, WO2005113606A2, WO2016102562A are known in the art.

[0097] In certain embodiments, the FGF21 domains provided herein comprise an amino acid sequence having at least 90% sequence identity to SEQ ID NO:1, while retaining substantial biological activity thereof.

[0098] In certain embodiments, the FGF21 domain comprises at most 12, 11, 10, 9, 8, 7 amino acid mutations (e.g., substitutions, insertions, or deletions) relative to SEQ ID NO: 1, while retaining substantial biological activity of SEQ ID NO: 1. In certain embodiments, the FGF21 domain comprises the amino acid sequences of SEQ ID NOs: 2-14, 16-19, 89-92, and 102-105.

[0099] In certain embodiments, FGF21 comprises one or more mutations.In certain embodiments, the one or more mutations comprise conservative substitutions.In certain embodiments, the one or more mutations are located at positions selected from the positions 121, 168, 171 and 180 relative to SEQ ID NO:1.

[0100] In certain embodiments, one or more mutations in FGF21 domain are selected from N121Q, M168L, P171G and A180E, or any combination thereof.For example, the FGF21 domain in the polypeptide disclosed herein can contain any one of four mutations, two of four mutations, three of four mutations, or four of mutations.

[0101] In certain embodiments, the FGF21 domain is 1) N121Q, 2) M168L; 3)A180E; 4) N121Q and M168L; 5) N121Q and A180E; 6) M168L and A180E; 7) N121Q, P171G, and A180E; 8) N121Q, M168L, and P171G; 9) M168L, P171G, and A180E; and 10) N121Q, M168L, P171G, and A180E The combination of mutations in relation to SEQ ID NO:1 is selected from the group consisting of:

[0102] In certain embodiments, the FGF21 domain may comprise the amino acid sequence set forth in SEQ ID NO:2 (N121Q), SEQ ID NO:3 (M168L), SEQ ID NO:4 (A180E), SEQ ID NO:5 (N121Q, M168L, and A180E), SEQ ID NO:89 (N121Q and M168L), SEQ ID NO:90 (N121Q and A180E), SEQ ID NO:91 (M168L and A180E), or SEQ ID NO:14 (N121Q, M168L, P171G, and A180E).

[0103] In certain embodiments, the FGF21 domain in the polypeptide further comprises a conjugable residue or up to one conjugable residue to which the functional moiety is conjugated.

[0104] The term "conjugable residue" as used herein refers to an amino acid residue at a particular position in a polypeptide that not only has a functional group that can be chemically or enzymatically conjugated to a chemical moiety, but also makes its position in the polypeptide amenable to such conjugation in a conjugation reaction for that particular functional group. As used herein, "conjugation" refers to a reaction that joins two molecules together to form one physical entity. For example, a covalent bond that links two molecules can be formed in conjugation. The conjugable residue can be a natural amino acid residue, a non-natural amino acid residue, a modified amino acid residue, or an amino acid mimic. Examples of conjugable residues include, but are not limited to, lysine, cysteine, or a non-natural amino acid residue.

[0105] Those skilled in the art will understand that whether a residue is a conjugable residue will depend on a given conjugation reaction and / or the functional group to be conjugated. For example, if the functional group to be conjugated is a thiol group and / or the conjugation reaction is specific or selective for thiol groups, then lysine (i.e., does not have a functional thiol group on its side chain) will not be considered a conjugable residue regardless of its position, whereas an unpaired cysteine ​​residue that does not form a disulfide bond (whether intrachain or interchain) may be a conjugable residue.

[0106] In certain embodiments, the polypeptide comprises a conjugable residue for thiol group-specific or selective conjugation reaction (e.g., maleimide reaction, or reaction for disulfide bond formation). When referring to an amino acid residue, the term "conjugable" is intended to mean that the residue at a particular position in the polypeptide is sufficiently available for conjugation. For example, a cysteine ​​residue as part of a disulfide bridge is not a conjugable residue in the present disclosure.

[0107] In certain embodiments, the conjugable residue is a cysteine ​​residue, preferably a free cysteine ​​residue that is not part of a disulfide bridge.

[0108] In certain embodiments, the conjugable residue CR in the FGF21 domain of the polypeptide provided herein may be at a position within the C-terminal fragment of the FGF21 domain, such as a position ranging from 169 to 181 relative to SEQ ID NO: 1. Further optionally, the conjugable residue may be at a position selected from the group consisting of 169, 170, 171, 172, 173, 174, 180, and 181 relative to SEQ ID NO: 1. Without wishing to be bound by any theory, it has been found by the inventors that conjugation at the C-terminal fragment of the FGF21 domain reduces C-terminal degradation of the FGF21 domain.

[0109] In certain embodiments, the FGF21 domain in the polypeptide has a combination of mutations: 1) N121Q and M168L, 2) N121Q, M168L, and P171G, 3) N121Q, M168L, and A180E, or 4) N121Q, M168L, P171G, and A180E, and further comprises conjugable residues (e.g., cysteine ​​residues) at positions 169, 170, 171, 172, 173, 174, or 180, 181 relative to SEQ ID NO:1.

[0110] In certain embodiments, the FGF21 domain in the polypeptide has a combination of N121Q and M168L mutations, or a combination of N121Q, M168L, and P171G mutations, and further comprises a conjugable residue (e.g., a cysteine ​​residue) at position 180 relative to SEQ ID NO:1.

[0111] In certain embodiments, the FGF21 domain in the polypeptide has a combination of mutations of N121Q, P171G, and M168L, or a combination of mutations of N121Q, M168L, P171G, and A180E, and further comprises an introduced cysteine ​​residue (e.g., by substitution) at the following listed positions relative to SEQ ID NO:1: 169, 170, 172, 173, or 174.

[0112] In certain embodiments, the FGF21 domain in the polypeptide has an amino acid sequence that includes an introduced cysteine ​​residue at position 169 (e.g., SEQ ID NO:6), 170 (e.g., SEQ ID NO:7), 171 (e.g., SEQ ID NO:8), 172 (e.g., SEQ ID NO:9), 173 (e.g., SEQ ID NO:10), 174 (e.g., SEQ ID NO:11 or SEQ ID NO:92), 180 (e.g., SEQ ID NO:12), or 181 (e.g., SEQ ID NO:13). In certain embodiments, FGF21 includes the amino acid sequences of SEQ ID NOs:2-5, 89-91, 14, and 102-105, except for one or more amino acid residue mutations at positions selected from positions 121, 168, 171, and 180, respectively, relative to SEQ ID NO:1.

[0113] In certain embodiments, the FGF21 domain in the polypeptide has an introduced G at position 171 (e.g., SEQ ID NO: 14). Without wishing to be bound by any theory, the present inventors find that the introduction of 171G in the FGF21 domain can also be useful in reducing C-terminal degradation of the FGF21 domain.

[0114] In certain embodiments, the FGF21 domain in the polypeptide has a combination of mutations of N121Q, P171G, and M168L, or a combination of mutations of N121Q, M168L, P171G, and A180E, and further comprises a conjugable residue at the positions listed below relative to SEQ ID NO:1: an introduced T at positions 172, 173, 174, where the positions are relative to SEQ ID NO:1; or an introduced N at positions 170 or 174, where the positions are relative to SEQ ID NO:1.

[0115] In certain embodiments, the FGF21 domain in the polypeptide has an introduced T at position 172 (e.g., SEQ ID NO: 16) or 173 (e.g., SEQ ID NO: 17); or an introduced N at position 170 (e.g., SEQ ID NO: 18) or 174 (e.g., SEQ ID NO: 19), relative to SEQ ID NO: 1. In certain embodiments, the FGF21 domain in the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-19.

[0116] Functional moieties on the FGF21 domain In the first and second embodiments of the polypeptides shown in Figures 1A and 1B, either or both of the polypeptides 001A and 001B may be optionally conjugated to a functional moiety 800 at the conjugable residue CR (illustrated by "*" in both figures) in the second fragment 200 (i.e., the FGF21 domain), thereby forming a polypeptide conjugate. In certain other embodiments, the polypeptide is not conjugated to a functional moiety, for example when the polypeptide has an introduced G at position 171.

[0117] The term "conjugate" as used herein refers to a compound resulting from two or more molecules joined together to form one physical entity. For example, the polypeptides of the present disclosure may form a polypeptide conjugate, which is essentially a compound resulting from the polypeptide and functional moiety joined together, according to certain embodiments. The molecules (e.g., functional moiety and polypeptide) may be attached together by covalent bonds, non-covalent bonds, linkers, chemical modifications, or protein fusion, or by any means known to those skilled in the art. Preferably, the molecules may be attached together by covalent bonds. The attachment may be permanent or reversible. In some embodiments, certain cleavable or non-cleavable linkers may be included.

[0118] The term "functional moiety" as used herein refers to a moiety that can functionally alter biological, pharmacokinetic (PK), or pharmacodynamic (PD) properties (e.g., enhance biological activity, increase in vitro stability, increase in vivo half-life, or enhance binding to a target receptor, etc.). The functional moiety conjugated to the FGF2 domain can optionally include a glycosyl moiety or a synthetic chemical moiety.

[0119] Optionally, the functional moiety 800 may comprise a synthetic chemical moiety and the conjugable residue CR may be an introduced residue that can be conjugated to the synthetic chemical moiety.

[0120] According to some embodiments, the conjugable residue CR may be an introduced cysteine ​​residue at any of the above-mentioned positions 169, 170, 171, 172, 173, 174, 180, and 181 relative to SEQ ID NO: 1. As used herein, the synthetic chemistry moiety may optionally comprise the structure *-XYZ, where X, Y, and Z are interconnected via bonds, and the * end of X is connected to a conjugable residue on the polypeptide. As used herein, X is

[0121] [ka] Y may be

[0122] [ka] Z may be

[0123] [ka] where the α position is linked to the α' position and the β position is linked to the β' position. As used herein, R1 can be hydrogen or -COOH; d can be 1, 2, or 3; a can be 1, 2, or 3; b can be 1, 2, or 3; c can be 1 or 2; d can be 1, 2, or 3; e can be 1, 2, or 3.

[0124] According to some embodiments, the synthetic chemical moiety can be Ac-2XADO-EDA-CO-CH2*, where the * terminus is

[0125] [ka] is connected to a conjugable cysteine ​​residue on a polypeptide having the structure:

[0126] In each of the above embodiments of FGF21 domains containing an introduced cysteine ​​residue at their respective positions as indicated above, whose sequences are set forth in SEQ ID NOs: 6-13 and 92, a synthetic chemical moiety such as Ac-2XADO-EDA-CO-CH2-* may be conjugated at the introduced cysteine ​​residue (e.g., by substitution), thereby obtaining a polypeptide conjugate bearing the synthetic chemical moiety.

[0127] In a polypeptide bearing a conjugated functional moiety, the functional moiety 800 may optionally comprise a glycosyl moiety, and accordingly the conjugable residue CR may be an introduced residue that is glycosylatable (i.e., capable of being glycosylated), which may be an introduced T at position 172 or 173, or an introduced N residue at position 170 or 174, relative to SEQ ID NO:1.

[0128] In each of the above embodiments of FGF21 domains containing an introduced T or N at their respective positions as indicated above, whose sequences are set forth in SEQ ID NOs: 16-19, a glycosyl moiety may be conjugated to the introduced cysteine ​​residue, thereby obtaining a polypeptide conjugate bearing a glycosyl moiety.

[0129] In certain embodiments, the FGF21 domain comprises an introduced G at position 171 relative to SEQ ID NO: 1 and is not conjugated to a functional moiety. In certain embodiments, such an FGF21 domain may comprise the amino acid sequence of SEQ ID NO: 14.

[0130] Nanobody Domain Each of the first and second embodiments of the polypeptides disclosed herein and illustrated in Figures 1A and 1B comprises a Nanobody domain.

[0131] The term "nanobody" as used herein is considered interchangeable with "single domain antibody" and refers to an antibody fragment containing a single variable domain of a heavy chain or a single variable domain of a light chain. Nanobodies contain three complementarity determining regions (CDRs). In certain embodiments, nanobodies can bind to a specific antigen (e.g., serum albumin).

[0132] The term "serum albumin" as used herein refers to albumin (a type of globular protein) found in vertebrate blood. Serum albumin is produced by the liver, exists dissolved in plasma, and is the most abundant blood protein in mammals. Serum albumin typically has a half-life of around 3 weeks, and it is mainly regulated by fetal Fc receptor (FcRn). FcRn protects serum albumin from intracellular degradation by binding to it with high affinity, diverting it from the lysosomal pathway and returning it to the extracellular compartment. In some embodiments, serum albumin is selected from human serum albumin (HSA), cynomolgus serum albumin, and mouse serum albumin. In some embodiments, the serum albumin provided herein is HSA.

[0133] The term "antibody" as used herein includes any immunoglobulin that binds to a specific antigen. A conventional antibody (e.g., an antibody of human or mouse origin) comprises two heavy (H) chains and two light (L) chains. Heavy chains are classified as α, δ, ε, γ, and μ, with each heavy chain consisting of a variable domain (VH domain) and a first, second, third, and optionally a fourth constant region (CH1, CH2, CH3, CH4, respectively); light chains are classified as λ or κ, while each light chain consists of a variable domain (VL domain) and a constant domain. Antibodies have a "Y" shape, with the stem of the Y consisting of the second and third constant domains of two heavy chains that are bound together via disulfide bonds. Each arm of the Y comprises the variable domain and the first constant domain of a single heavy chain that is bound to the variable and constant domains of a single light chain. The variable domains of the light and heavy chains are involved in antigen binding. The variable domains in both chains generally contain three hypervariable regions called complementarity determining regions (CDRs, ie CDR1, CDR2 and CDR3 in the light or heavy chain).The CDR boundaries for the antibodies and antigen-binding fragments disclosed herein may be defined or specified by the Kabat, IMGT, Chothia, or Al-Lazikani conventions (Al-Lazikani, B., Chothia, C., Lesk, A.M., J. Mol. Biol., 273(4), 927(1997); Chothia, C. et al., J Mol Biol. Dec 5; 186(3):651-63(1985); Chothia, C. and Lesk, A.M., J. Mol. Biol., 196, 901(1987); Chothia, C. et al., Nature. Dec 21-28; 342(6252):877-83(1989); Kabat EA et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991); Marie-Paule Lefranc et al., Developmental and Comparative Immunology, 27:55-77 (2003); Marie-Paule Lefranc et al., Immunome Research, 1(3), (2005); Marie-Paule Lefranc, Molecular Biology of B cells (second edition), chapter 26, 481-514, (2015)). The three CDRs are interposed between adjacent stretches known as framework regions (FRs, i.e. FR1, FR2, FR3, and FR4 of the light or heavy chain), which are more highly conserved than the CDRs and form a scaffold supporting the highly variable loops. The constant domains of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions. Conventional antibodies are assigned to classes based on the amino acid sequence of the constant domain of their heavy chains.

[0134] The single variable domain may be derived from the variable domain of a camelid antibody (VHH domain) or the variable domain of a chondric antibody (VNAR domain). Both camelid and chondric antibodies naturally lack light chains and consist of a pair of heavy chains. Alternatively, the single variable domain may be derived from the variable domain of a conventional antibody (e.g., from human or mouse) heavy chain (VH domain) or the variable domain of a common antibody light chain (VL domain). It is contemplated that single domain antibodies are fairly small in size, for example having a molecular weight of at most 25 kD, at most 20 kD, at most 15 kD, or at most 10 kD.

[0135] It should be noted that the term "nanobody" or "single domain antibody" is used herein in its broadest sense and is not limited to a specific biological source or to a specific method of preparation. For example, single domain antibodies can be obtained, for example, by (1) isolating the VHH or VNAR domain of a naturally occurring heavy chain antibody; (2) by expression of a nucleotide sequence encoding a naturally occurring VHH or VNAR domain; (3) by "humanization" (described below) of a naturally occurring VHH or VNAR domain, or by expression of a nucleic acid encoding such a humanized VHH or VNAR domain; (4) by "camelization" of a naturally occurring VH domain from any animal species, particularly a mammalian species, such as from humans, or by expression of a nucleic acid encoding such a camelized VH domain; 5) using synthetic or semi-synthetic techniques to prepare proteins, polypeptides, or other amino acid sequences; and / or (6) any combination of the above. Appropriate methods and techniques for carrying out the above will be apparent to those skilled in the art.

[0136] In some embodiments, the single domain antibodies described herein comprise VHH domains derived from antibodies made in Camelidae species, such as camel, dromedary, alpaca, and guanaco. Single domain antibodies comprising VHH domains are highly soluble and stable to heat, pH, proteases, and other denaturing agents or conditions.

[0137] In some embodiments, the first polypeptide fragment comprises one or more single domain antibodies capable of specifically binding to serum albumin.

[0138] The terms "binding specificity", "specific binding" or "specifically binds" in reference to the interaction of a binding molecule, such as an antibody, and its binding partner, such as an antigen, mean that the interaction is dependent on the presence of a particular structure, such as an antigenic determinant or epitope, on the binding partner. In other words, an antibody preferentially binds to or recognizes its binding partner even when it is present in a mixture of other molecules or organisms. An antibody or fragment thereof that immunospecifically binds to an antigen may be cross-reactive with related antigens that carry the same epitope. "Binding specificity" is generally measured against non-specific background binding. Typically, an antibody is considered specific when it binds to a target antigen at least 10-fold above background binding.

[0139] The serum-binding single domain antibodies contemplated herein may bind or alternatively be associated with serum albumin such that the binding of said serum albumin molecule to FcRn is not (significantly) reduced or inhibited (i.e. compared to the binding of said albumin molecule to FcRn when the single domain antibody is not bound thereto). In this embodiment of the invention, "not significantly reduced or inhibited" means that the binding affinity for serum albumin to FcRn (measured using a suitable assay such as SPR) is not reduced by more than 10%, such as not reduced by more than 50%, preferably not reduced by more than 30%, even more preferably not reduced by more than 5%, or essentially not reduced at all. In this embodiment, "not significantly reduced or inhibited" may also mean that the half-life of the serum albumin molecule is not significantly reduced (e.g., not reduced by more than 10%, such as not reduced by more than 50%, preferably not reduced by more than 30%, even more preferably not reduced by more than 5%, or essentially not reduced at all, measured using a suitable technique known per se). In some embodiments, the single domain antibody may bind to amino acid residues on serum albumin that are not involved in the binding of serum albumin to FcRn.

[0140] In some embodiments, the single domain antibody described herein binds to serum albumin selected from HSA, cynomolgus serum albumin, and mouse serum albumin.In some embodiments, the binding affinity to mouse serum albumin is approximately weaker than that to human or cynomolgus serum albumin.In some embodiments, the single domain antibody specifically binds to HSA.

[0141] In some embodiments, the single domain antibodies described herein bind to serum albumin with sufficient binding affinity. The term "affinity" as used herein refers to the strength of non-covalent interactions between an immunoglobulin molecule (i.e., an antibody) or fragment thereof and an antigen. Affinity can be expressed numerically using a "Kd" value. Generally, a lower Kd value corresponds to stronger binding. Kd can be determined by using any conventional method known in the art, including, but not limited to, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR) methods, microscale thermophoresis, HPLC-MS methods, and flow cytometry (such as FACS) methods. In some embodiments, the antibodies disclosed herein bind to a specific antigen with a binding affinity of ≦10 -6 M (e.g., ≦5×10 -7 M, ≤2×10 -7 M, ≦10 -7 M, ≤5×10 -8 M, ≤2×10 -8 M, ≦10 -8 M, ≤5×10 -9 M, ≤4×10 -9 M, ≤3×10 -9 M, ≤2×10 -9 M, or ≤ 10 -9 M)K d It has a value.

[0142] In certain embodiments, the single domain antibodies provided herein comprise -5 M~1×10 -12 Less than M, 10 -7 M~1×10 -12 Less than M or 10 -8 M~1×10 -12 In some embodiments, the Kd is at most 1×10 -7 M (e.g., at most 5 × 10 -7 M, at most 2 × 10 -7 M, at most 10 -7 M, at most 5 × 10 -8 M, at most 2 × 10-8 M, at most 10 -8 M, at most 5 × 10 -9 M, at most 4 × 10 -9 M, at most 3 × 10 -9 M, at most 2 × 10 -9 M, or at most 10 -9 M).

[0143] In some embodiments, the single domain antibody provided herein is a humanized antibody. The term "humanized" as used herein means that the single domain antibody comprises CDRs derived from a non-human animal and FR regions derived from a human. Humanized antibody polypeptides are desirable for their reduced immunogenicity in humans. Humanized antibody polypeptides are chimeric in their variable regions because non-human CDR sequences are grafted onto human or substantially human FR sequences. Humanization of antibody polypeptides can be essentially performed by substituting non-human (such as camelid) CDR genes for the corresponding human CDR genes in human immunoglobulin genes (see, for example, Jones et al. (1986) Nature 321:522-525; Riechmann et al. (1988) Nature 332:323-327; Verhoeyen et al. (1988) Science 239:1534-1536).

[0144] Various single domain antibodies capable of specifically binding to HSA with high affinity are known in the art, such as fully human domain antibodies isolated using phage display, VHH antibodies developed from the camelidae family, and VNAR antibodies developed from cartilaginous fishes, see Zorzi, A et al, Med Chem Commun, 2019, 10, 1068.Exemplary HSA-binding single domain antibodies are described in US8188223B2, US9067991B2, US9321832B2, PCT applications WO2008028977A2, WO2008043822A2, WO2020099871A1, G. Winter, et al, Annu. Rev. Immunol., 1994, 12, 433-455., LJ Holt, et al., Protein Eng., Des. Sel., 2008, 21(5), 283-288, A. Walker, et al., Protein Eng., Des. Sel., 2010, 23(4), 271-278, LJ Goodall, et al., PLoS One,2015,10(9),e0137065, RLO'Connor-Semmes,et al.,Clin.Pharmacol.Ther.,2014,96(6),704-712,C.Read,et al.,Basic Clin.Pharmacol.Toxicol.,2019,1-8,R.Adams,et al.,mAbs,2016,8(7),1336-1346, E.Dave,et al.,mAbs,2016,8(7),1319-1335, S.Steeland,et al.,Drug Discovery Today,2016,21(7),1076-1113, K.Coppieters,et al.,Arthritis Rheum.,2006,54(6),1856-1866, M. Van Roy,,et al.,Arthritis Res. Ther., 2015, 17, 135; C. McMahon, et al., Nat. Struct. Mol. Biol., 2018, 25(3), 289-296; MR Muller, et al., mAbs, 2012, 4(6), 673-685, all of which are contemplated within the scope of this disclosure and incorporated by reference.

[0145] In some embodiments, the single domain antibody comprises a VHH domain. In some embodiments, the VHH domain is humanized.

[0146] In some embodiments, the VHH domain comprises complementarity determining region 1 (CDR1), CDR2 and CDR3, wherein CDR1 comprises the sequence of SEQ ID NO: 20 (SFGMS) or a variant thereof having up to 3, 2 or 1 amino acid mutations, CDR2 comprises the sequence of SEQ ID NO: 21 (SISGSGSDTLYADSVKG) or a variant thereof having up to 3, 2 or 1 amino acid mutations, and / or CDR3 comprises the sequence of SEQ ID NO: 22 (GGSLSR) or a variant thereof having up to 3, 2 or 1 amino acid mutations, and wherein the VHH domain retains binding specificity to serum albumin, optionally to human serum albumin.

[0147] In some embodiments, the VHH domain comprises a complementarity determining region 1 (CDR1) comprising the sequence of SEQ ID NO:20, a CDR2 comprising the sequence of SEQ ID NO:21, and a CDR3 comprising the sequence of SEQ ID NO:22.

[0148] In some embodiments, the VHH domain comprises a complementarity determining region 1 (CDR1) consisting of the sequence of SEQ ID NO:20, a CDR2 consisting of the sequence of SEQ ID NO:21, and a CDR3 consisting of the sequence of SEQ ID NO:22.

[0149] In some embodiments, the VHH domain comprises the sequence of SEQ ID NO:23, or a variant thereof having at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 99%) identity to SEQ ID NO:23, wherein the variant retains binding specificity and / or affinity for serum albumin.

[0150] In some embodiments, a variant of SEQ ID NO:23 has up to 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations relative to SEQ ID NO:23.

[0151] In certain embodiments of the polypeptide illustrated in Figure 1A, the serum albumin binding Nanobody domain further comprises an N-terminal extension attached to the VHH domain. In certain embodiments, the N-terminal extension comprises an amino acid residue of SG, AG, S, or A, and thus may comprise an amino acid sequence selected from SEQ ID NOs: 24-27.

[0152] In certain embodiments, the N-terminal extension comprises a tag, optionally a cleavable tag. Without wishing to be bound by any theory, it is believed that certain N-terminal extensions may be useful for expression and post-translational processing.

[0153] In certain embodiments, the serum albumin binding Nanobody domain does not comprise an N-terminal extension attached to the VHH domain, for example, the VHH domain may be attached to a cleavable tag that is no longer present in the final product after cleavage.

[0154] In some embodiments, the first fragment may comprise one or more serum albumin binding Nanobody domains.

[0155] GLP-1 domain A second embodiment of the polypeptide disclosed herein and illustrated in FIG. 1B further comprises a third fragment 300 that comprises, in addition to the above-described FGF21 domain in the second fragment 200 and the serum albumin binding Nanobody domain in the first fragment 100, an additional functional domain.

[0156] According to some embodiments, the additional functional domain comprises a biologically active GLP-1 domain.

[0157] The term "glucagon-like peptide-1" or "GLP-1" as used herein is intended to broadly encompass the native GLP-1 peptide and all its functional forms, such as its functional variants, fragments, fusions, derivatives, and mimetics.

[0158] As used herein, the term "native GLP-1 peptide" refers to native human glucagon-like peptide-1 (GLP-1(7-37)), the sequence of which is set forth in SEQ ID NO: 28. The numbering of residues in GLP-1 begins with the H residue at position 7 and ends with the G residue at position 37, with reference to the sequence of SEQ ID NO: 28.

[0159] A functional form of a native GLP-1 peptide may activate the GLP-1 receptor at a level comparable to or at least 20% (or at least 30%, 40%, 50%, 60%, 70%, 80%, 90%) of that of the native GLP-1 peptide. Activation of the GLP-1 receptor typically initiates a signal transduction pathway that leads to insulin secretion stimulation or other physiological effects, as known in the art. Many functional forms of GLP-1 peptides are known in the art, including, but not limited to, liraglutide, semaglutide, dulaglutide, albiglutide, and those disclosed in WO2000055203A1, WO98 / 08871, WO2006 / 097537, WO2007139589A1, WO1998019698A1, WO2001098331A2, WO2003040309A2, WO2005000892A2, WO2015000942A1, WO2016083499A1, the disclosures of which are incorporated herein in their entireties.

[0160] In certain embodiments, the GLP-1 domain provided herein comprises an amino acid sequence having at least 70% (e.g., at least 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%) sequence identity to SEQ ID NO:28, while retaining substantial biological activity of SEQ ID NO:28.

[0161] In certain embodiments, the GLP-1 domain comprises at most 9, 8, 7, 6, 5, 4, 3, or 2 substitutions relative to SEQ ID NO: 28, while retaining substantial biological activity of SEQ ID NO: 28. In certain embodiments, the GLP-1 domain comprises at least 2, 3, 4, 5, 6, 7, 8, or 9 substitutions relative to SEQ ID NO: 28, while retaining substantial biological activity of SEQ ID NO: 28.

[0162] In certain embodiments, the GLP-1 domain further comprises one or more mutations. Examples of amino acid substitutions include substituting an L-amino acid for its corresponding D-amino acid, substituting cysteine ​​for homocysteine ​​or other non-natural amino acids with thiol-containing side chains, substituting lysine for homolysine, diaminobutyric acid, diaminopropionic acid, ornithine, or other non-natural amino acids with amino-containing side chains, or substituting alanine for norvaline or the like.

[0163] Various substitutions have been introduced into natural GLP-1 peptide and have been shown to retain or even improve its biological activity.In certain embodiments, GLP-1 comprises one or more mutations at positions selected from the group consisting of A8, G22, K34, R36, and H7, and / or any combination thereof, relative to SEQ ID NO:28.For example, substitution at A8 is useful for blocking DPP4 enzymatic cleavage at this residue, substitution at G22 is desirable for improving activity and solubility, and substitution at R36 is useful for reducing immunogenicity.In certain embodiments, GLP-1 comprises one or more mutations at positions selected from the group consisting of A8, G22, K26, K34, and R36, and / or any combination thereof, relative to SEQ ID NO:28. Examples of substitutions at these positions include, but are not limited to, A8G, A8S, A8V, A8Aib, A8T, A8I, A8L, G22E, K26R, K34R, R36G, or any combination thereof, as well as the substitutions described in U.S. Patent No. 8,273,854, which is incorporated herein by its entirety. In certain embodiments, the one or more additional substitutions comprise a conservative substitution.

[0164] In certain embodiments, the GLP-1 domain comprises an A8 substitution selected from the group consisting of A8G, A8S, A8V, A8Aib, A8T, and A8L. In certain embodiments, the GLP-1 domain comprises a G22E substitution. In certain embodiments, the GLP-1 domain comprises an R36G n substitution. In certain embodiments, the GLP-1 domain comprises a K26 substitution that is K26R. In certain embodiments, the GLP-1 domain comprises a K34 substitution that is K34R.

[0165] In certain embodiments, GLP-1 comprises or consists of one or more substitutions selected from the group consisting of A8G, K26R, K34R, G22E, and R36G. In certain embodiments, GLP-1 comprises or consists of one or more substitutions selected from the group consisting of A8G, G22E, and R36G.

[0166] In the present disclosure, at least the following embodiments of the biologically active GLP-1 domain in the third fragment 300 in FIG. 1B are provided:

[0167] (1) SEQ ID NO:28, which represents the wild-type functional form of GLP-1;

[0168] (2) SEQ ID NO:29, which represents a three-substituted functional form of GLP-1, containing substitutions A8G, G22E, and R36G;

[0169] (3) SEQ ID NO:31, which represents a 4-substituted functional form of GLP-1, containing substitutions A8G, G22E, K34R, and R36G;

[0170] (4) SEQ ID NO:32, which represents a 5-substituted functional form of GLP-1, containing the substitutions A8G, G22E, K26R, K34R, and R36G;

[0171] (4) SEQ ID NO:33, which represents a 5-substituted functional form of GLP-1, containing the substitutions A8G, G22E, K26R, K34R, and R36K; and

[0172] (5) SEQ ID NO:34, which represents a 4-substituted functional form of GLP-1, containing the substitutions A8G, G22E, K26R, and R36G.

[0173] In addition to GLP-1, the additional functional domains of the third fragment 300 illustrated in FIG. 1B include insulin, C-peptide, leptin, glucagon, gastrin, gastric inhibitory polypeptide (GIP), amylin, calcitonin, cholecystokinin, peptide YY, neuropeptide Y, bone morphogenetic protein-6 (BMP-6), bone morphogenetic protein-9 (BMP-9), oxyntomodulin, oxytocin, glucagon-like peptide-2 (GLP-2), irisin, fibronectin, and ribozyme. It should be noted that the IL-10 receptor agonist may alternatively include biologically active forms (i.e., functional forms) of IFNDC5, apelin, adiponectin, Clq and tumor necrosis factor-related protein (CTRP family), resistin, visfatin, omentin, retinol-binding protein-4 (RBP-4), glicentin, angiopoietin, interleukin-22 (IL-22), exendin-4, or growth hormone.

[0174] First and / or second linker Each of the first and second embodiments of the polypeptide disclosed herein and illustrated in Figures 1A and 1B utilizes a first linker 10 to connect a first fragment 100 (comprising a Nanobody domain capable of binding to serum albumin) and a second fragment 200 (comprising a biologically active FGF21 domain), and the second embodiment of the polypeptide illustrated in Figure 1B utilizes a second linker 20 to connect the first fragment 100 and a third fragment 300 (comprising a biologically active additional functional domain, such as a GLP-1 domain, that has an additive or synergistic effect on the FGF21 domain).

[0175] The term "linker" as used herein, such as first linker 10 and / or second linker 20, generally refers to a "polypeptide linker," which may be any suitable polypeptide that can bind two entities, thereby forming one molecule, or that is in sufficient proximity to maintain the association of the two entities, but without substantial interference with the biological activity of each of the two entities.

[0176] Linkers may be incorporated into the resulting linked molecule or structure. Herein, the first linker 10 operably separates the Nanobody domain 100 and the FGF21 domain 200 without substantial interference with the respective biological activities of the two functional domains, and the second linker 20 operably separates the GLP-1 domain and the Nanobody domain 100 without substantial interference with the respective biological activities of the two functional domains. The linker may be composed of amino acid residues linked together by peptide bonds, but may optionally further comprise one or more unnatural amino acids.

[0177] Generally, each of the first linker 10 and the second linker 20 has a length of at least 4 amino acid residues. Thus, in certain embodiments, each linker has a length of at least 4, 8, 10, 20, 24, 28, 30, 40, 48, 50, 60, 70, 80, 90, 100, 110, 120 or more amino acid residues. Without wishing to be bound by any theory, it is believed that the appropriate length of the linker can further improve the biological activity, stability or pharmacokinetic parameters of each of the two functional domains thus linked in the whole polypeptide molecule.

[0178] Any suitable polypeptide may be used as a linker. For example, a polypeptide linker may comprise or consist of amino acid residues selected from the amino acids glycine (G), serine (S), alanine (A), methionine (M), asparagine (N), glutamine (Q), cysteine ​​(C), proline (P), glutamic acid (E), threonine (T) and lysine (K). In some embodiments, a polypeptide linker may be composed of a majority of amino acids that are sterically unhindered, such as glycine and alanine. In some embodiments, the linker is polyglycine, polyalanine, a combination of glycine and alanine (such as poly(Gly-Ala)), or a combination of glycine and serine (such as poly(Gly-Ser)).

[0179] In certain embodiments, each of the first linker and the second linker comprises or consists of one or more repeats of the repeat sequence. In certain embodiments, the polypeptide linker comprises or consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 repeats of the repeat sequence, or any number within the range defined by any two numbers listed above.

[0180] Based on the experimental data presented in the Examples below, the following configurations are provided herein, which are nevertheless optional and non-limiting in scope.

[0181] Regarding the first linker, it may not contain an acidic amino acid residue (e.g., D or E) according to some embodiments. The first linker may optionally contain one or more units of a first repeat sequence, and the first repeat sequence may consist of at most 4 or 6 types of amino acid residues, which may be selected from the group consisting of G, Q, A, P, T, and S. According to some embodiments of the polypeptide, the first repeat sequence may consist of at most 4 or 6 types of amino acid residues, which may be selected from the group consisting of G, Q, A, P, T, and S. f S g(each of f and g is independently an integer selected from 1 to 5), SEQ ID NO:35 (GAQP), SEQ ID NO:36 (GQAP), SEQ ID NO:37 (GPAQ), SEQ ID NO:38 (GPQA), SEQ ID NO:39 (GSQP), SEQ ID NO:40 (GASP), SEQ ID NO:41 (GPAS), SEQ ID NO:42 (GPSA), SEQ ID NO:43 (GGGS), SEQ ID NO:44 (GSGS), SEQ ID NO:45 (GGGGS), SEQ ID NO:46 (GSAPGSPAGSPTGSAPGSPA), and GS. In certain embodiments of the polypeptide, the first repeat sequence has the amino acid sequence set forth in SEQ ID NO:35 (GAQP), and the number of the one or more units is an integer from 1 to 10. In certain embodiments, the first linker comprises an amino acid sequence set forth in SEQ ID NO:35 (GAQP), SEQ ID NO:49 ((GAQP)2), SEQ ID NO:50 ((GAQP)5), SEQ ID NO:51 ((GAQP) 10 ), and SEQ ID NO: 48 (GGGGSGGGS).

[0182] With regard to the second linker, it may similarly comprise one or more units of a second repeat sequence, and the second repeat sequence may consist of at most 4 or 6 types of amino acid residues selected from the group consisting of G, Q, A, E, P, T, and S. In certain embodiments of the polypeptide, the second repeat sequence may consist of at most 4 or 6 types of amino acid residues selected from the group consisting of G, Q, A, E, P, T, and S. h S i(each of h and i is independently an integer selected from 1 to 5), comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:35 (GAQP), SEQ ID NO:55 (GQEP), SEQ ID NO:56 (GEQP), SEQ ID NO:57 (GPQE), SEQ ID NO:58 (GPEQ), SEQ ID NO:59 (GSEP), SEQ ID NO:60 (GESP), SEQ ID NO:61 (GPSE), SEQ ID NO:62 (GPES), SEQ ID NO:36 (GQAP), SEQ ID NO:37 (GPAQ), SEQ ID NO:38 (GPQA), SEQ ID NO:39 (GSQP), SEQ ID NO:40 (GASP), SEQ ID NO:41 (GPAS), SEQ ID NO:42 (GPSA), SEQ ID NO:43 (GGGS), SEQ ID NO:44 (GSGS), SEQ ID NO:45 (GGGGS), SEQ ID NO:46 (GSAPGSPAGSPTGSAPGSPA), and GS. In certain embodiments, the second repeat sequence has the amino acid sequence set forth in SEQ ID NO: 35 (GAQP), and the number of one or more units is an integer from 1 to 15, optionally 1, 2, 5, 10, or 14. In certain embodiments, the second linker has the amino acid sequence set forth in SEQ ID NO: 49 ((GAQP)2), SEQ ID NO: 50 ((GAQP)5), SEQ ID NO: 51 ((GAQP) 10 ), and SEQ ID NO:52 ((GAQP) 14 ), and SEQ ID NO: 47 ((GGGGS)4).

[0183] In certain embodiments, each of the first linker and the second linker can comprise or consist of more than one repeat sequence.For example, one such linker can comprise or consist of 2, 3, or 4 different repeat sequences.In certain embodiments, one such linker can comprise or consist of consecutive or tandem repeats of different repeat sequences.The number of repeats of each repeat sequence can be independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more.

[0184] Other notes With respect to each of the FGF21 domain, nanobody domain, GLP-1 domain, and first / second linker described above, the following is noted. Those skilled in the art will understand that various amino acid substitutions, such as conservative amino acid substitutions, can be made in any of the sequences of the polypeptide fragments described herein without necessarily reducing their activity. Examples of amino acid substitutions include substituting an L-amino acid for its corresponding D-amino acid, substituting cysteine ​​for homocysteine ​​or other non-natural amino acids with thiol-containing side chains, substituting lysine for homolysine, diaminobutyric acid, diaminopropionic acid, ornithine, or other non-natural amino acids with amino-containing side chains, or substituting alanine for norvaline or the like.

[0185] "Conservative substitution" in relation to amino acid sequence refers to replacing an amino acid residue with a different amino acid residue that has a side chain with similar physicochemical properties.For example, conservative substitution can be made between amino acid residues with hydrophobic side chains (e.g., Met, Ala, Val, Leu, and Ile), between residues with neutral hydrophilic side chains (e.g., Cys, Ser, Thr, Asn, and Gln), between residues with acidic side chains (e.g., Asp, Glu), between amino acids with basic side chains (e.g., His, Lys, and Arg), or between residues with aromatic side chains (e.g., Trp, Tyr, and Phe).As is known in the art, conservative substitution usually does not cause significant changes in protein conformation, and therefore can retain the biological activity of protein.

[0186] The following full length sequences are provided for certain embodiments for the first embodiment (illustrated in FIG. 1A) and the second embodiment (illustrated in FIG. 1B).

[0187] Certain embodiments of the polypeptide are substantially fusion polypeptides between a serum albumin binding Nanobody domain and an FGF21 domain, in the N-terminal to C-terminal direction, and may have an amino acid sequence selected from SEQ ID NOs: 63-68, 93, 99-101, and 107. In certain of these embodiments, the polypeptide is conjugated to a synthetic chemical moiety provided herein (see, for example, based on FIG. 1A). The synthetic chemical moiety may be, for example, Ac-2XADO-EDA-CO-CH2-*, which is conjugated to an introduced cysteine ​​residue at position 171 or 174 relative to SEQ ID NO: 1 for a polypeptide having a sequence selected from the group consisting of SEQ ID NOs: 63, 68, 93, and 100. In certain alternative embodiments, the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 64-67, 69, 99, and 108 and is not conjugated.

[0188] Table 1A below shows SEQ ID NOs for exemplary fusion polypeptide sequences, as well as the SEQ ID NOs for the Nanobody, FGF21, and the first and second polypeptide linkers contained in the fusion polypeptide.

[0189] [Table 1A]

[0190] Certain embodiments of the polypeptide are substantially fusion polypeptides between, in the N-terminal to C-terminal direction, the GLP-1 domain, the serum albumin binding Nanobody domain, and the FGF21 domain, which may have an amino acid sequence selected from SEQ ID NOs: 70, 74, 75, 79-83, 85, 94-98, and 108-109. In certain of these embodiments, the polypeptide is conjugated to a synthetic chemical moiety provided herein (see, for example, based on FIG. 1B). The synthetic chemical moiety may be, for example, Ac-2XADO-EDA-CO-CH2-*, which is conjugated to an introduced cysteine ​​residue at position 171 or 174 relative to SEQ ID NO: 1 for an amino acid sequence selected from the group consisting of SEQ ID NOs: 74, 81-83, 85, 94, 96, and 97. In certain alternative embodiments, the polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 70, 75, 79, 80, 95, 98, and 108-109 and is not conjugated.

[0191] Table 1B below shows the sequence numbers of exemplary fusion polypeptide sequences, as well as the sequence numbers for the GLP-1 domain, the first polypeptide linker, the nanobody, the FGF21 domain, and the first and second polypeptide linkers contained in the fusion polypeptide.

[0192] [Table 1B-1] [Table 1B-2]

[0193] Pharmaceutical Compositions In another aspect, the present disclosure further provides a pharmaceutical composition comprising a polypeptide according to any of the embodiments described above, and a pharma- ceutically acceptable carrier.

[0194] The term "pharmaceutical acceptable" indicates that the specified carrier, vehicle, diluent, excipient, and / or salt is generally chemically and / or physically compatible with the other ingredients comprising the formulation, and physiologically compatible with the recipient thereof.

[0195] "Pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation other than the active ingredient that is acceptable to a subject and is non-toxic biologically active. Pharmaceutically acceptable carriers for use in the pharmaceutical compositions disclosed herein may include, for example, pharma-ceutically acceptable liquid, gel, or solid carriers, aqueous vehicles, non-aqueous vehicles, antimicrobial agents, isotonicity agents, buffers, antioxidants, anesthetics, suspending / dispersing agents, sequestering or chelating agents, diluents, adjuvants, excipients, or other non-toxic auxiliary substances, or various combinations thereof known in the art.

[0196] Suitable components may include, for example, antioxidants, fillers, binders, disintegrants, buffers, preservatives, lubricants, flavorings, thickeners, colorants, emulsifiers, or stabilizers, such as sugars and cyclodextrins. Suitable antioxidants may include, for example, methionine, ascorbic acid, EDTA, sodium thiosulfate, platinum, catalase, citric acid, cysteine, thioglycerol, thioglycolic acid, thiosorbitol, butylated hydroxyanisol, butylated hydroxytoluene, and / or propyl gallate. As disclosed herein, the inclusion of one or more antioxidants, such as methionine, in the pharmaceutical compositions provided herein reduces oxidation of the polypeptide complex or bispecific polypeptide complex. This reduction in oxidation prevents or reduces the decrease in binding affinity, thereby improving protein stability and maximizing shelf life. Thus, in certain embodiments, compositions are provided that include the polypeptide, polypeptide complex, or conjugate disclosed herein and one or more antioxidants, such as methionine.

[0197] To further illustrate, pharma- ceutically acceptable carriers may include, for example, aqueous vehicles such as Sodium Chloride Injection, Ringer's Injection, Isotonic Dextrose Injection, Sterile Water Injection, or Dextrose and Lactated Ringer's Injection; non-aqueous vehicles such as fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil, or peanut oil; antimicrobial agents in bacteriostatic or fungistatic concentrations; isotonic agents such as sodium chloride or dextrose; buffers such as phosphate or citrate buffers; antioxidants such as sodium bisulfate; local anesthetics such as procaine hydrochloride; suspending and dispersing agents such as sodium carboxymethylcellulose, hydroxypropyl methylcellulose, or polyvinylpyrrolidone; emulsifying agents such as polysorbate 80 (TWEEN-80); Antimicrobial agents used as carriers, including phenol or cresol, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride, and benzethonium chloride, can be added to the pharmaceutical composition in multi-dose containers. Suitable excipients can include, for example, water, saline, dextrose, glycerol, or ethanol. Suitable non-toxic auxiliary substances can include, for example, wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or agents such as sodium acetate, sorbitan monolaurate, triethanolamine oleate, or cyclodextrin.

[0198] The pharmaceutical compositions can be liquid solutions, suspensions, emulsions, pills, capsules, tablets, sustained release formulations, or powders. Oral formulations can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, polyvinyl pyrollidone, sodium saccharin, cellulose, magnesium carbonate, etc.

[0199] In an embodiment, the pharmaceutical composition is formulated into an injectable composition.The injectable pharmaceutical composition can be prepared in any conventional form, such as liquid solution, suspension, emulsion, or solid form suitable for making liquid solution, suspension, or emulsion.The preparation for injection can include sterile and / or non-pyrogenic solution ready for injection, sterile dry soluble product such as lyophilized powder ready for mixing with solvent immediately before use, including hypodermic tablets, sterile suspension ready for injection, sterile dry insoluble product ready for mixing with vehicle immediately before use, and sterile and / or non-pyrogenic emulsion.The solution can be either aqueous or non-aqueous.

[0200] In certain embodiments, unit dose parenteral preparations are packaged in an ampoule, vial, or syringe with a needle. All preparations for parenteral administration must be sterile and nonpyrogenic, as known and practiced in the art.

[0201] In certain embodiments, a sterile lyophilized powder is prepared by dissolving a polypeptide, polypeptide complex or conjugate disclosed herein in a suitable solvent. The solvent may contain excipients that improve the stability or other pharmacological components of the powder or the reconstituted solution prepared from the powder. Excipients that may be used include, but are not limited to, water, dextrose, sorbital, fructose, corn syrup, xylitol, glycerin, glucose, sucrose, or other suitable agents. The solvent may contain a buffer such as citrate, sodium or potassium phosphate, or other such buffers known to those skilled in the art, in one embodiment at approximately neutral pH. Subsequent sterile filtration of the solution, followed by lyophilization under standard conditions known to those skilled in the art, provides the desired formulation. In one embodiment, the resulting solution will be apportioned into vials for lyophilization. Each vial may contain a single or multiple doses of a polypeptide, polypeptide complex, or conjugate, or composition thereof, provided herein. Overfilling the vial with a small amount (e.g., about 10%) beyond that needed for a dose or series of doses is permissible to facilitate accurate sample draws and accurate dosing. The lyophilized powder may be stored under appropriate conditions, such as at about 4° C. to room temperature.

[0202] Reconstitution of the lyophilized powder with water for injection provides a formulation for use in parenteral administration.In one embodiment, for reconstitution, sterile and / or nonpyrogenic water or other liquid suitable carrier is added to the lyophilized powder.The exact amount depends on the selected therapy being given and can be empirically determined.

[0203] Administration of the pharmaceutical compositions described herein can be via any route known to be effective by a physician of ordinary skill. One example is peripheral parenteral administration by a sterile syringe or some other mechanical device such as an infusion pump. In certain embodiments, the peripheral parenteral route is an intravenous, intramuscular, subcutaneous, or intraperitoneal route of administration.

[0204] In certain embodiments, the polypeptides, polypeptide complexes or conjugates described herein are formulated in a form suitable for parenteral routes of administration, such as oral, rectal, nasal, or lower respiratory routes of administration.

[0205] In certain embodiments, the polypeptide, polypeptide complex or conjugate described herein is formulated into a solid formulation, such as freeze-dried or spray-dried, which is then reconstituted in a suitable diluent solution before administration.Standard pharmaceutical formulation techniques can be adopted, such as those described in Remington: The Science and Practice of Pharmacy (DB Troy, Editor, 21st Edition, Lippincott, Williams & Wilkins, 2006).Alternatively, the polypeptide, polypeptide complex or conjugate described herein can be formulated for administration via lingual, sublingual, buccal, buccal, oral, gastric and intestinal, nasal, pulmonary, such as via bronchioles and alveoli or a combination thereof, epidermal, dermal, transdermal, vaginal, rectal, ocular, such as via conjunctiva, ureter, transdermal, or intrapulmonary route. As yet a further option, the polypeptides, polypeptide complexes or conjugates described herein may be formulated for administration transdermally, e.g., by needle-free injection or from a patch, optionally an iontophoretic patch, or via transmucosal, e.g., buccal administration.

[0206] Treatment Method In yet another aspect, the present disclosure further provides methods and kits for preventing or treating a metabolic disorder in a subject in need thereof.

[0207] The method essentially comprises administering to the subject a therapeutically effective amount of a polypeptide or pharmaceutical composition as described above.

[0208] As used herein, "treating" or "treatment" of a condition includes preventing or alleviating the condition, slowing the onset or progression of the condition, reducing the risk of developing the condition, preventing or delaying the onset of symptoms associated with the condition, reducing or terminating symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or any combination thereof.

[0209] As used herein, the term "subject" or "individual" or "animal" or "patient" refers to a human or non-human animal, including a mammal or primate, in need of diagnosis, prognosis, amelioration, prevention, and / or treatment of a disease or disorder. Mammalian subjects include humans, domestic animals, farm animals, and zoo, sport, or pet animals, such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, pigs, cows, bears, etc.

[0210] In certain embodiments, the subject has been identified as having a disorder or condition that may be responsive to a polypeptide or pharmaceutical composition provided herein.

[0211] In certain embodiments, the metabolic disorder is diabetes, obesity, non-alcoholic steatohepatitis (NASH), cardiovascular-like dyslipidemia, atherosclerosis, alcoholic steatohepatitis (ASH), diabetic nephropathy, gestational diabetes, metabolic syndromes such as metabolic syndrome X, non-alcoholic fatty liver disease (NAFLD), end-stage liver disease, hepatic steatosis (fatty liver), cirrhosis, primary biliary cirrhosis (PBC) or severe hypertriglyceridemia (SHTG).

[0212] For example, the metabolic conditions or disorders that can be treated or improved using the polypeptide or pharmaceutical composition provided herein include conditions in which a human subject has a fasting blood glucose level of 125 mg / dL or more, for example, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, or more than 200 mg / dL. Blood glucose level can be determined in a fed or fasted state, or randomly. Metabolic conditions or disorders can also include conditions in which a subject is at increased risk of developing a metabolic condition. For human subjects, such conditions include a fasting blood glucose level of 100 mg / dL.

[0213] The therapeutically effective amount of the polypeptide or pharmaceutical composition provided herein will depend on various factors known in the art, such as the subject's weight, age, medical history, current medication, health status, and potential for cross-reaction, allergy, sensitivity, and adverse side effects, as well as the route of administration and the extent of disease progression.Dosage amounts may be proportionally reduced or increased by a skilled artisan (e.g., a physician or veterinarian) as indicated by these and other circumstances or requirements.A therapeutically effective amount may be the amount of the polypeptide conjugate or pharmaceutical composition provided herein that elicits the biological or pharmaceutical response in a tissue system, animal, or human that is sought by a researcher, physician, or other clinician, including alleviating or improving the symptoms of the disease or disorder being treated, i.e., the amount that supports an observable level of one or more desired biological or pharmaceutical responses, such as lowering blood glucose, insulin, triglyceride, or cholesterol levels; lowering body weight; or improving glucose tolerance, energy expenditure, or insulin sensitivity.

[0214] In certain embodiments, a polypeptide or pharmaceutical composition provided herein may be administered at a therapeutically effective dosage of about 0.01 mg / kg to about 100 mg / kg (e.g., about 0.01 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, or about 100 mg / kg). In certain of these embodiments, the polypeptide or pharmaceutical composition provided herein is administered at a dosage of about 50mg / kg or less, and in certain of these embodiments, the dosage is 10mg / kg or less, 5mg / kg or less, 1mg / kg or less, 0.5mg / kg or less, or 0.1mg / kg or less.In certain of these embodiments, the dosage administered may vary over the course of treatment.For example, in certain of these embodiments, the dosage administered initially may be higher than the dosage administered subsequently.In certain of these embodiments, the dosage administered may vary over the course of treatment depending on the subject's response.

[0215] Dosage regimens can be adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single dose can be administered, or several divided doses can be administered over time.

[0216] A polypeptide or pharmaceutical composition provided herein may be administered by any route known in the art, such as, for example, parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, or intradermal injection) or non-parenteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.

[0217] The polypeptide or pharmaceutical composition may be administered alone or in combination with one or more additional therapeutic procedures or agents.

[0218] In certain embodiments, when used to treat metabolic disease, the polypeptide or pharmaceutical composition provided herein can be administered in combination with any other therapeutic agent for use in the treatment of metabolic disease or any related medical disorder. As used herein, "administered in combination" includes administration simultaneously as part of the same pharmaceutical composition, simultaneously as separate compositions, or at different times as separate compositions. A composition that is administered before or after another agent is considered to be administered "in combination" with that agent, as the phrase is used herein, even if the composition and the second agent are administered via different routes. When possible, the additional therapeutic agent administered in combination with the fusion polypeptide, polypeptide complex, or conjugate provided herein is administered according to the schedule listed in the product information sheet of the additional therapeutic agent, or according to the Physicians' Desk Reference (Physicians' Desk Reference, 70th Ed (2016)) or protocols well known in the art.

[0219] kit Also provided is a kit for carrying out the method for administering the pharmaceutical composition described above.Such a kit can include pharmaceutical compositions such as those described herein, which can be provided in a sterile container.Optionally, instructions on how to employ the pharmaceutical composition provided in the treatment of metabolic disorder can also be included or made available to patients or medical providers.

[0220] Such kits may include (a) a pharmaceutical composition comprising a therapeutically effective amount of the fusion polypeptide conjugate; and (b) one or more containers for the pharmaceutical composition. Such kits may also include instructions for its use; the instructions may be tailored to the exact metabolic disorder being treated. The instructions may describe the use and properties of the materials provided in the kit. In certain embodiments, the kits include instructions for the patient to administer to treat metabolic disorders such as elevated glucose levels, elevated insulin levels, diabetes, obesity, non-alcoholic steatohepatitis (NASH), cardiovascular-like dyslipidemia, atherosclerosis, alcoholic steatohepatitis (ASH), diabetic nephropathy, metabolic syndromes such as metabolic syndrome X, non-alcoholic fatty liver disease (NAFLD), end-stage liver disease, hepatic steatosis (fatty liver), cirrhosis, primary biliary cirrhosis (PBC) or severe hypertriglyceridemia (SHTG).

[0221] The instructions may be printed on a substrate such as paper or plastic and may be present in the kit as a package insert, on a label on the container of the kit or a component thereof (e.g., associated with the packaging), or the like. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer-readable storage medium, e.g., CD-ROM, diskette, or the like. In yet other embodiments, the actual instructions are not present in the kit, but a means is provided for obtaining the instructions from a remote source, such as through the Internet. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and / or from which the instructions can be downloaded. Often, it will be desirable for some or all of the components of the kit to be packaged in suitable packaging that maintains sterility. The components of the kit may be packaged in a kit storage element that creates a single, easily handled unit, and the kit storage element, e.g., a box or similar structure, may or may not be a hermetically sealed container, e.g., to further maintain sterility for some or all of the components of the kit.

[0222] Polynucleotides encoding polypeptides In yet another aspect, the present disclosure further provides a method for preparing the above described polypeptide (or optionally a polypeptide conjugate). To this end, the following are provided in the present disclosure:

[0223] First, the disclosure provides an isolated nucleic acid or polynucleotide encoding a fusion polypeptide described herein.

[0224] The term "nucleic acid" or "polynucleotide" as used herein refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof, either in single-stranded or double-stranded form.Unless specifically limited, the term encompasses polynucleotides that contain known analogues of natural nucleotides, which have similar binding properties as reference nucleic acids and are metabolized in a manner similar to naturally occurring nucleotides.Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses its conservatively modified variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0225] The nucleic acid or polynucleotide encoding the fusion polypeptide described herein can be constructed using recombinant techniques.For this purpose, the DNA encoding serum albumin binding nanobody, the DNA encoding FGF21 domain, and optionally the DNA encoding GLP-1 domain can be obtained and operably linked to allow transcription and expression in host cell to produce polypeptide.The polynucleotide sequence encoding polypeptide linker can also be operably linked to allow expression of desired product.

[0226] The coding polynucleotide sequence may further be operably linked to one or more regulatory sequences, optionally in an expression vector, so that expression or production of the fusion polypeptide is feasible and under proper control.

[0227] The coding polynucleotide sequence can be inserted into a vector for further cloning (amplification of DNA) or for expression using recombinant techniques known in the art. Many vectors are available. Vector components generally include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter (e.g., prokaryotic promoters such as T7, T7lac, Sp6, araBAD, trp, lac, tac, pLm, A3, lac, lpp, npr, pac, syn, trc, and T3, or eukaryotic promoters such as SV40, CMV, and EF-1α), and a transcription termination sequence.

[0228] Vectors and host cells Secondly and thirdly, the disclosure further provides a vector comprising the polynucleotide provided above, and a host cell comprising the vector described herein.

[0229] The term "vector" as used herein refers to a vehicle into which a polynucleotide encoding a protein can be operatively inserted to cause expression of the protein. A vector can be used to transform, transduce, or transfect a host cell to cause expression of the genetic element it carries in the host cell. Non-limiting examples of vectors include plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs), bacteriophages such as lambda phage or M13 phage, and animal viruses. Categories of animal viruses used as vectors include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex viruses), pox viruses, baculoviruses, papilloma viruses, and papova viruses (e.g., SV40). A vector can contain a variety of elements for controlling expression, including promoter sequences, transcription initiation sequences, enhancer sequences, selectable elements, and reporter genes. In addition, vectors may contain origins of replication. Vectors may also contain materials that aid their entry into cells, including but not limited to viral particles, liposomes, or protein coatings. Vectors may be expression vectors or cloning vectors. The present disclosure provides vectors (e.g., expression vectors) that contain the nucleic acid sequence provided herein that encodes a fusion polypeptide, at least one promoter (e.g., SV40, CMV, EF-1α) operably linked to the nucleic acid sequence, and at least one selectable marker.Examples of vectors include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g., herpes simplex virus), poxviruses, baculoviruses, papilloma viruses, papova viruses (e.g., SV40), lambda phage, and M13 phage, plasmids pcDNA3.3, pMD18-T, pOptivec, pCMV, pEGFP, pIRES, pQD-Hyg-GSeu, pALTER, pBAD, pcDNA, pCal, pL, pET, pGEMEX, pGEX, pCI, p These include, but are not limited to, EGFT, pSV2, pFUSE, pVITRO, pVIVO, pMAL, pMONO, pSELECT, pUNO, pDUO, Psg5L, pBABE, pWPXL, pBI, p15TV-L, pPro18, pTD, pRS10, pLexA, pACT2.2, pCMV-SCRIPT.RTM., pCDM8, pCDNA1.1 / amp, pcDNA3.1, pRc / RSV, PCR2.1, pEF-1, pFB, pSG5, pXT1, pCDEF3, pSVSPORT, pEF-Bos, and the like.

[0230] As used herein, the phrase "host cell" refers to a cell into which an exogenous polynucleotide and / or vector has been introduced.

[0231] The vector comprising the polynucleotide sequence provided herein can be introduced into host cells for cloning or gene expression.As used herein, the term "host cell" refers to the cell into which exogenous polynucleotide and / or vector is introduced.In other embodiments, the vector is extrachromosomal.If desired, the host cell can be isolated.In certain embodiments, the host cell is a prokaryotic cell, and in some other embodiments, the host cell is a eukaryotic cell.

[0232] The host cell suitable for cloning or expressing the DNA in the vector herein is mainly prokaryote.Prokaryote suitable for this purpose includes eubacteria such as gram-negative or gram-positive organisms, for example, Escherichia, Enterobacteriaceae such as E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, such as Salmonella typhimurium, Serratia, such as Serratia marcescans and Shigella, and Bacilli such as B.subtilis and B.licheniformis, Pseudomonas such as P.aeruginosa, and Streptomyces.In some embodiments, host cell is eukaryote, such as yeast and mammalian cell (e.g., immortalized mammalian cell).

[0233] The vector comprising the polynucleotide sequence provided herein can be introduced into host cells using any suitable method known to those skilled in the art, such as transformation, transfection or transduction.In one example, the polynucleotide sequence encoding fusion polypeptide can be subcloned into an expression vector, which is expressed as inclusion body in host cells.The vector can be a viral vector, and any suitable viral vector can be used in this capacity.

[0234] In this specification, the host cell can be a prokaryotic cell or a eukaryotic cell. The host cell transformed with the above-described expression or cloning vector can be cultured in a conventional nutrient medium, modified as necessary, for inducing promoters, selecting transformants, or amplifying cloning vectors.

[0235] In another aspect, the disclosure provides a method of producing a fusion polypeptide described herein, comprising culturing a host cell provided herein under conditions that allow expression of the fusion polypeptide described herein.

[0236] For the production of the fusion polypeptides described herein, the host cells transformed with the expression vectors can be cultured in a variety of media. Commercially available bacterial growth media such as Terrific Broth, LB Broth, LB Agar, M9 Minimal Medium, MagiaMedia Medium, and ImMedia Medium (ThermoFisher) are suitable for culturing bacterial host cells. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium (MEM) (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle Medium (DMEM) (Sigma) are suitable for culturing eukaryotic host cells. Any of these media may be supplemented as necessary with hormones and / or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as the GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to one of skill in the art. Culture conditions such as temperature, pH, etc. will be those previously used with the host cell selected for expression and will be apparent to one of skill in the art.

[0237] Methods for Producing Polypeptides In one embodiment, the disclosure provides a method of expressing a fusion polypeptide described herein, comprising culturing a host cell provided herein under conditions in which the fusion polypeptide described herein is expressed.

[0238] In certain embodiments, the fusion polypeptide is expressed as inclusion bodies. In certain embodiments, the method further comprises renaturing the fusion polypeptide from the inclusion bodies.

[0239] When using recombinant techniques, the fusion polypeptides described herein can be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the product is produced intracellularly, as a first step, particulate debris, whether host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio / Technology 10:163-167 (1992) describes a procedure for isolating proteins secreted into the periplasmic space of E. coli. Briefly, cell paste is thawed in the presence of sodium acetate (pH 3.5), EDTA, and phenylmethylsulfonyl fluoride (PMSF) for about 30 minutes. Cell debris can be removed by centrifugation. If the product is secreted into the medium, the supernatant from such expression systems is generally first concentrated using a commercially available protein concentration filter, for example, an Amicon or Millipore Pellicon ultrafiltration unit. A protease inhibitor such as PMSF may be included in any of the foregoing steps to inhibit proteolysis, and antibiotics may be included to prevent the growth of adventitious contaminants.

[0240] In certain embodiments, the method further comprises isolating the fusion polypeptide.

[0241] The fusion polypeptides described herein prepared from cells can be purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, DEAE-cellulose ion exchange chromatography, ammonium sulfate precipitation, salting out, and affinity chromatography.

[0242] Other techniques for protein purification such as fractionation on ion exchange columns, ethanol precipitation, reverse phase HPLC, chromatography on silica, chromatography on heparin SEPHAROSE™ chromatography on anion or cation exchange resins (such as polyaspartic acid columns), chromatofocusing, SDS-PAGE, and ammonium phosphate precipitation can also be used depending on the protein of interest to be recovered.

[0243] Also provided in the present disclosure is a method or process for producing the above-described polypeptide, which essentially comprises the following two steps:

[0244] S100: Culturing the host cell described above under conditions allowing expression of the polynucleotide defined above, or a precursor thereof further comprising a removable tag; and

[0245] S200: Recovering and purifying the polypeptide or its precursor from the host cell.

[0246] In certain embodiments, the polypeptide is expressed as an inclusion body. In certain embodiments, the method further comprises recovering the polypeptide from the inclusion body to allow it to refold. Furthermore, according to some embodiments, the host cell is E. coli, the vector comprises an E. coli compatible vector, and the polypeptide encoded by the polynucleotide in the vector is codon-optimized for E. coli expression.

[0247] When using recombinant techniques, the polypeptides described herein can be produced intracellularly, in the periplasmic space, or directly secreted into the medium.When the product is produced intracellularly, as a first step, particulate debris, whether host cells or lysed fragments, is removed, for example, by centrifugation or ultrafiltration.

[0248] According to some embodiments, the step S200 of recovering and purifying the polypeptide from the host cell may include the following substeps:

[0249] S210: recovering a precursor of the polypeptide;

[0250] S220: refolding a precursor of the polypeptide;

[0251] S230: treating the refolded precursor of the polypeptide to remove the tag, thereby obtaining the polypeptide; and

[0252] S240: Purifying the polypeptide.

[0253] In certain embodiments, the host cells are lysed and the polypeptide or a precursor of the polypeptide is obtained from the insoluble fraction containing the polypeptide or a precursor of the polypeptide.

[0254] According to some embodiments of the polypeptide production process, the process further comprises conjugating the purified polypeptide with a functional moiety. In certain embodiments, the functional moiety to be conjugated to the polypeptide is

[0255] [ka] (Ac-2XADO-EDA-CO-CH2-*). EXAMPLES

[0256] [Example 1] Recombinant expression of Nanobody-FGF21 protein and GLP-1-Nanobody-FGF21 The GLP-1-Nanobody-FGF21 proteins or Nanobody-FGF21 fusion proteins listed in Tables 1A and 1B, as well as Table 1C, were produced from a bacterial E. coli expression system using the BL21(DE3) derivative strain. DNA encoding the GLP-1-Nanobody-FGF21 fusion precursor or Nanobody-FGF21 fusion protein was codon-optimized for E. coli expression, de novo synthesized, and subcloned into a PET derivative expression vector (Novagen). Amino acid substitutions were accomplished by modification of the corresponding genetic code. Overexpression of the GLP-1-Nanobody-FGF21 fusion precursor or Nanobody-FGF21 fusion protein was induced with 0.5 mM isopropyl bd-thiogalactoside (IPTG) when the cell density reached an OD600 of 2.0 in Terrific Broth (TB) medium. After protein induction at 37°C for 20-22 hours, the cells were harvested.

[0257] [Table 1C]

[0258] [Example 2] Purification of nanobody-FGF21 protein Cells were harvested and lysed in 20 mM Tris pH 8.0, 0.15 M NaCl buffer by cell disruption (900 bar, 2 times). The insoluble fraction containing the nanobody-FGF21 fusion protein was collected by centrifugation (8,000×g, 30 min). After refolding, the fusion protein was purified by anion exchange chromatography. Samples at each step were characterized by LC / MS to confirm the correct molecular weight.

[0259] [Example 3] Purification of GLP-1-Nanobody-FGF21 Cells were harvested and lysed in 20 mM Tris pH 8.0, 0.15 M NaCl buffer by cell disruption (900 bar, 2 times). The insoluble fraction containing the GLP-1-Nanobody-FGF21 fusion precursor was collected by centrifugation (8,000×g, 30 min). After refolding, the fusion protein precursor was captured by anion exchange chromatography. After tag removal by protease, the protein was purified by hydrophobic interaction chromatography. Samples at each step were characterized by LC / MS to confirm the correct molecular weight.

[0260] [Example 4] Preparation of Nanobody-FGF21 and GLP-1-Nanobody-FGF21 fusion protein conjugates To a solution of Nanobody-FGF21 or GLP-1-Nanobody-FGF21 fusion protein in Tris buffer, Ac-2XADO-EDA-CO-CH2-Br in organic solvent was added dropwise. The reaction was stirred at room temperature for 1 hour. The products were then applied to anion exchange chromatography. This provided the compounds listed in Table 1 shown above.

[0261] The conjugated fusion proteins were detected and characterized by LC-MS methods using a Waters BioAccord LC-MS system or by UPLC using a Waters Acquity UPLC system, using conditions optimized for the different conjugates according to the supplier's manual.

[0262] [Example 5] In vitro activity Methods: In vitro GLP-1 activity of the fusion proteins was measured using a BHK cell line overexpressing human GLP-1 receptor and CRE luciferase reporter in the presence or absence of 1% human serum albumin (HSA). Test fusion proteins were measured at 100 nM as the top concentration in the presence of 1% HSA using 3-fold serial dilutions. After treating the cells with the molecules for 4 hours, luciferase activity was measured by Steadylite plus kit (Perkin Elmer, 6066751).

[0263] The activity of each fusion protein was expressed by an EC50 derived from nonlinear regression analysis.

[0264] The in vitro FGF21 activity of the fusion protein was assessed using a HEK293 cell line that overexpresses human beta-Klotho. The test fusion protein conjugate was measured at a top concentration of 400 nM using 4-fold serial dilutions in the presence of 1% HSA. After cells were treated with the fusion protein conjugate for 12 minutes, p-ERK levels were measured by p-ERK kit (Cisbio, 64ERKPEH).

[0265] The activity of each fusion protein was calculated using the EC 50 It is expressed by.

[0266] Conclusion: As shown in Tables 2 and 3, all fusion proteins showed comparable efficacy to native FGF21. However, the fusion molecules (MLC#9, MLC#10, MLC#12, MLC#13, MLC#14, MLC#15, MLC#16, MLC#17, MLC#19, and MLC#21) exhibited different GLP-1 activity. Molecules MLC#14, MLC#16, MLC#17, MLC#19, and MLC#21 showed significantly higher GLP1 activity than MLC#9, MLC#12, MLC#13, and MLC#15. Compared with other fusion molecules tested, MLC#15 has a relatively shorter second linker and also has lower GLP-1 activity. Taken together, this may indicate that fusion molecules with longer second linkers may have higher GLP1 activity. As shown in Figures 2A and 2B, the fusion molecules (MLC#9, MLC#10, control#6, and MLC#14) showed significantly higher FGF21 potency than the YH-dual molecule (i.e., the molecule disclosed as sequence number 66 in WO2017 / 074123).

[0267] [Table 2]

[0268] [Table 3]

[0269] [Example 6] Efficacy studies in disease models Selected molecules are assessed in disease animal models (db / db mice, diet-induced obese (DIO) mice, etc.) to determine body weight, food intake, glucose efficacy with respect to dose response in chronic studies. Several biomarkers are also measured, including plasma insulin, plasma triglycerides, plasma cholesterol, plasma LDL-c, plasma adiponectin, liver triglycerides, liver cholesterol, and liver function indices (ALT, AST).

[0270] A) Food intake and weight loss method: 22-week-old DIO male C57BL / 6 mice (approximately 50 g) were injected subcutaneously every other day (Q2D) with the indicated GLP-1 polypeptide conjugate (i.e., molecule 012) for 25 days. Food intake and body weight were measured twice a week, and fasting blood glucose was measured once a week. Five animals were used for each treatment group. Body weight and fasting blood glucose were monitored for each individual animal, while food intake for each group animal was measured together. Days 1 and 25 represent the first and last days of molecule dosing. Data are presented as mean and standard error (SEM) or pooled values. Statistical analysis was performed by one-way ANOVA. Body weight loss on day 25 is calculated by -1*(% BW loss-% BW loss of vehicle group); cumulative food intake loss is calculated by -100*(cumulative food intake-cumulative food intake of vehicle) / cumulative food intake of vehicle.

[0271] Conclusion: In the DIO study, molecular control #2, control #6, MLC #9, and MLC #10 have significant effects on weight loss and food intake suppression, as shown in Figures 3A, 3B, and Table 8.

[0272] [Table 8]

[0273] B) Metabolic parameters in DIO animal models method: Sixteen-week-old DIO male C57BL / 6 mice (35–40 g) were injected subcutaneously once daily (QD) with the indicated GLP-1 / FGF21 conjugates (i.e., MLC#9, MLC#14, MLC#16, and MLC#17) for 21 days. Food intake and body weight were measured once daily, and nonfasting blood glucose was measured once every 3 days. Five animals were used for each treatment group. Body weight and blood glucose were monitored for each individual animal, whereas food intake for each group of animals was measured together. Days 1 and 21 were the first and last days of treatment, respectively. Terminal blood was collected, and EDTA-K3 plasma was prepared and frozen at -80°C for biomarker measurements (LDL-C, TC, TG, ALT, insulin, adiponectin). Liver and adipose tissue were also collected, frozen in liquid nitrogen, and stored at -80°C. Data are shown as mean and standard error (SEM) or pooled values. Statistical analysis was performed by one-way ANOVA. Body weight loss on day 21 is calculated by -1*(BW loss%-BW loss% of vehicle group); cumulative food intake loss is calculated by -100*(cumulative food intake-cumulative food intake of vehicle) / cumulative food intake of vehicle.

[0274] Conclusion: In a DIO mouse study, the molecules MLC#9, MLC#14, MLC#16, and MLC#17 showed much better efficacy in weight loss compared to semaglutide, tirzepatide, and YH-dual (SEQ ID NO: 66 in WO2017 / 074123), as shown in FIG. 4A. MLC#9, MLC#14, MLC#16, and MLC#17 induced about 30-35% weight loss in the study. In contrast, semaglutide, tirzepatide, and YH-dual induced about 20%-25% weight loss.

[0275] In Figure 4B, the MLC#9, MLC#14, MLC#16, and MLC#17 groups showed better glucose control than semaglutide, tirzepatide, and YH-dual. MLC#9, MLC#14, MLC#16, and MLC#17 reduced non-fasting glucose levels to below 7 mmol / L. In contrast, semaglutide reduced non-fasting glucose to approximately 7.5-10 mmol / L.

[0276] MLC#9, MLC#14, MLC#16, and MLC#17 induced improvements in hepatic TG (Figure 4I), hepatic TC (Figure 4J), and insulin sensitivity (Figure 4K), as well as decreases in plasma triglyceride (Figure 4C), LDL-C (Figure 4D), total cholesterol (Figure 4E), and ALT (Figure 4F) concentrations, as well as decreases in fat weight (Figure 4G) and liver weight (Figure 4H).

[0277] In vivo, FGF21 can induce the secretion of adiponectin, which is reported to be an insulin sensitizer. Fusion molecules MLC#9, MLC#14, MLC#16, and MLC#17 showed better effects on increasing adiponectin levels than YH-dual, which showed better FGF21 activity (Figure 4L).

[0278] C) Metabolic parameters in an ob / ob animal model at different dosages. Methods: Ten-week-old ob / ob male mice (42-55 g) were injected subcutaneously once daily (QD) with the indicated GLP-1 / FGF21 conjugates (i.e., MLC#14 and MLC#16) for 14 days. Food intake and body weight were measured once daily. Non-fasting blood glucose was measured once every 3 days. Plasma triglyceride (TG) levels were measured once weekly. Five or six animals were used for each treatment group. Body weight and blood glucose were monitored for each individual animal, whereas food intake for each group animal was measured together. Days 1 and 14 were the first and last days of molecular dosing. On day 14 after treatment, mice were sacrificed by cardiac puncture under anesthesia. Terminal blood was collected and frozen at -80°C for biomarker measurements (LDL-C, TC, TG, ALT / AST, insulin, adiponectin). Liver and adipose tissue were also collected, frozen in liquid nitrogen, and stored at -80°C. Data are shown as mean and standard error (SEM) or pooled values. Statistical analysis was performed by one-way ANOVA. Body weight loss on day 14 is calculated by -1*(BW loss%-BW loss% of vehicle group); cumulative food intake loss is calculated by -100*(cumulative food intake-cumulative food intake of vehicle) / cumulative food intake of vehicle.

[0279] Conclusion: In ob / ob mice studies, the fusion molecules MLC#14 and MLC#16 showed dose-dependent efficacy on weight loss (FIG. 5A), glucose lowering, and biomarker changes, as shown in FIG. 5A-5M. In FIG. 5A, the molecules MLC#14 and MLC#16 showed much better efficacy on weight loss compared to the same dosage of semaglutide, tirzepatide, and YH-dual (SEQ ID NO: 66 in WO2017 / 074123). In FIG. 5B, the MLC#14 and MLC#16 groups reached a similar effect on glucose control with the same dosage of semaglutide. As shown in FIG. 5C, MLC#14 and MLC#16 induced a better reduction in plasma triglycerides compared to the same dosage of semaglutide, tirzepatide, and YH-dual. MLC#14 and MLC#16 also reduced the levels of LDL-C (Fig. 5D), total cholesterol (Fig. 5E), ALT (Fig. 5F), and AST (Fig. 5G) concentrations in plasma, as well as the reduction of fat weight (Fig. 5H) and liver weight (Fig. 5I), along with the improvement of liver TG (Fig. 5J), liver TC (Fig. 5K), and insulin sensitivity (Fig. 5L). The fusion molecules MLC#14 and MLC#16 showed significantly better effects on increasing adiponectin levels than the same dosage of YH-dual, which showed better FGF21 activity (Fig. 5M).

[0280] D) Metabolic parameters in DIO animal models Methods: Sixteen-week-old DIO male C57BL / 6 mice (35-50 g) were injected subcutaneously once daily (QD) with the indicated GLP-1 / FGF21 conjugates and FGF21 conjugates (i.e., MLC#16, MLC#19, MLC#6, and MLC#23) for 22 days. Food intake and body weight were measured once every 3 days, and fasting blood glucose was measured weekly. Five animals were used for each treatment group. Body weight and blood glucose were monitored for each individual animal, but food intake for each group of animals was measured together. Days 1 and 22 were the first and last days of treatment, respectively. Terminal blood was collected, and EDTA-K3 plasma was prepared and frozen at -80°C for biomarker measurements (LDL-C, TC, TG). Liver and adipose tissue were also collected, frozen in liquid nitrogen, and stored at -80°C. Data are presented as mean and standard error (SEM) or pooled values. Statistical analysis was performed by one-way ANOVA.

[0281] conclusion In a DIO mouse study, GLP-1-nanobody-FGF21 fusion protein conjugates (MLC#16 and MLC#19) and nanobody-FGF21 fusion conjugates (MLC#6 and MLC#23) showed good efficacy for weight loss, as shown in Figure 6A. In Figure 6B, the MLC#16, MLC#19, MLC#6, and MLC#23 groups showed better glucose control than semaglutide, and also induced a reduction in serum triglyceride (Figure 6C), LDL-C (Figure 6D), and total cholesterol (Figure 6E) concentrations in plasma, as well as a reduction in fat weight (Figure 6F) and liver weight (Figure 6G), along with improved liver TG (Figure 6H).

[0282] [Example 7] Pharmacokinetic studies in rats Methods: Male SD rats aged 6-8 weeks were administered a single subcutaneous dose of 15 nmol / kg protein MLC#9 (conjugated) or MLC#10 (unconjugated) (n=3 / group). Plasma samples were collected before dosing (-5 min), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 32 h, 48 h, 72 h, and 96 h after subcutaneous administration. Concentrations of polypeptide conjugates in plasma were measured by ELISA. Pharmacokinetic parameters were calculated by WinNonlin based on the graphs showing plasma concentration vs. time for each polypeptide conjugate after subcutaneous injection.

[0283] Conclusion: MLC#9 has a T half-life of 14.3 hours in rats. 1 / 2 It has a half-life T of 9.5 hours. 1 / 2 This shows a longer half-life than MLC#10, which has

[0284] [Example 8] PK study in minipigs The pharmacokinetics of selected molecules are assessed in minipigs. Both subcutaneous and intravenous injections are performed.

[0285] [Example 9] PK study in non-human primates The pharmacokinetics of selected molecules are assessed in monkeys. Both subcutaneous and intravenous injections are performed.

[0286] Methods: Male cynomolgus monkeys aged 4-5 years were administered a single subcutaneous dose of 5 mg / kg (123 nmol / kg) MLC#16 (n=2 / group). Plasma samples were collected pre-dose (-5 min), 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 36 h, 48 h, 72 h, 96 h, 120 h, 144 h, and 168 h after subcutaneous administration. MLC#16 in plasma was measured by LC-MS / MS method. Pharmacokinetic parameters were calculated by WinNonlin based on the graph showing plasma concentration of MLC#16 vs. time after subcutaneous injection.

[0287] Conclusions: MLC#16 exhibited a half-life of 54.3 hours in monkeys, which potentially supports a once weekly dosing frequency in humans (Table 9).

[0288] [Table 9]

[0289] [Example 10] Immunogenicity assessment Selected GLP-1 polypeptide conjugates are also assessed for immunogenicity by in silico (iTope and TCED methods) and ex vivo (EpiScreen) methods.

[0290] [Example 11] Stability Assessment To test the stability, various GLP-1 polypeptide conjugates are formulated in buffers with different compositions (pH 6, 7, 7.4, and 8.0) and stored at different temperatures (such as 4°C and 25°C) for 2-4 weeks. %HMWP and %LMW are analyzed by size-exclusion chromatography (SEC)-HPLC. Concentration and modification are analyzed by reversed-phase (RP)-UPLC and LC / MS.

[0291] [Example 12] Human serum albumin binding Methods: Binding of molecules to serum albumin was characterized by surface plasmon resonance on a Biacore 8K instrument. Human serum albumin was covalently coupled to the CM5 sensor chip surface until 4000RU was reached. The chip was blocked with 1M ethanolamine for 420 seconds at a flow rate of 10 μL / min. Each molecule sample was diluted and injected at a flow rate of 30 μL / min to allow binding to the albumin bound to the chip for 120 seconds and dissociation for 300 seconds. Binding buffer without molecules was pumped over the chip at a flow rate of 20 seconds to allow spontaneous dissociation of the bound molecules for 30 seconds.

[0292] Conclusion: All fusion molecules (MLC#9, MLC#10, Control#4, Control#5, Control#6, MLC#12, and MLC#16) show similar binding affinity to human serum albumin (see Table 10).

[0293] [Table 10]

[0294] [Example 13] FAP enzyme cleavage on the fusion protein Methods: Fibroblast activation protein (FAP) is a serine protease. This enzyme has been reported to regulate the degradation of FGF21. To test the C-terminal degradation of fusion proteins by FAP enzyme, fusion proteins (MLC#23, MLC#25) and FAP enzyme were incubated at a ratio of 200:1 at 37°C for 20 hours. LC-MS was performed to analyze the degradation percentage of the fusion proteins.

[0295] Conclusion: The fusion proteins without conjugation (MLC#25, MLC#18, and MLC#21) showed 50.6-65.2% C-terminal degradation upon incubation with FAP enzyme for 20 h at 37° C. However, the fusion protein conjugates (MLC#23, MLC#16, and MLC#19), and the fusion protein with the 171G substitution (MLC#10) showed resistance to the FAP enzyme.

[0296] [Table 11]

Claims

1. In the N-terminal to C-terminal direction, a first fragment comprising a Nanobody domain capable of binding to serum albumin, wherein said Nanobody domain comprises a VHH domain, said VHH domain comprising a complementarity determining region 1 (CDR1) comprising the sequence of SEQ ID NO: 20, a CDR2 comprising the sequence of SEQ ID NO: 21, and a CDR3 comprising the sequence of SEQ ID NO: 22; and a second fragment comprising a biologically active FGF21 domain, wherein the FGF21 domain comprises one or more amino acid residue mutations selected from the group consisting of N121Q, M168L, P171G and A180E, or any combination thereof, relative to SEQ ID NO:1; A polypeptide comprising: the first fragment and the second fragment are connected via a first linker; A polypeptide, wherein the first linker comprises one or more units of a first repeat sequence, the first repeat sequence consisting of at most four or six types of amino acid residues selected from the group consisting of G, Q, A, P, T and S.

2. 2. The polypeptide of claim 1, wherein the FGF21 domain further comprises a conjugable residue, the conjugable residue comprising an introduced cysteine residue.

3. the conjugable residue is at a position within the C-terminal fragment spanning positions 169 to 181 relative to SEQ ID NO:1; and optionally The conjugable residue is located at a position selected from the group consisting of positions 169, 170, 171, 172, 173, 174, 180, and 181 relative to SEQ ID NO:1; The polypeptide of claim 2.

4. The polypeptide of claim 2, wherein the FGF21 domain comprises the amino acid sequence of SEQ ID NOs: 6-13, and 92.

5. The conjugable residue in the second fragment is conjugated to a functional moiety, the functional moiety comprising a synthetic chemical moiety, the synthetic chemical moiety comprising the structure *-X-Y-Z, where X, Y, and Z are interconnected via bonds and the * end of X is connected to the conjugable residue on the polypeptide, wherein: X is 【Chemical 1】 Y may be [Chemical Formula 2] Z may be [Chemical 3] It may be In the formula, the α-position is linked to the α'-position, the β-position is linked to the β'-position, R1 is hydrogen or -COOH; d is 1, 2, or 3; a is 1, 2, or 3; b is 1, 2, or 3; c is 1 or 2; d is 1, 2, or 3; e is 1, 2, or 3, the polypeptide according to claim 2.

6. The synthetic chemical part has the following structure: 【Chemical Formula 4】 The polypeptide according to claim 5, which has.

7. The introduced cysteine is at position 171, and optionally, the FGF21 domain contains the amino acid sequence of SEQ ID NO: 8, the polypeptide according to claim 6.

8. i) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 6, and the introduced cysteine is at position 169; ii) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 7, and the introduced cysteine is at position 170; iii) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 9, and the introduced cysteine is at position 172; iv) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 10, and the introduced cysteine is at position 173; v) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 11, and the introduced cysteine is at position 174; vi) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 12, and the introduced cysteine is at position 180; vii) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 13, and the introduced cysteine is at position 181, or viii) The FGF21 domain contains the amino acid sequence of SEQ ID NO: 92, and the introduced cysteine is at position 174, The polypeptide according to claim 6.

9. The FGF21 domain further contains substitution P171G in relation to SEQ ID NO: 1, the polypeptide according to claim 1.

10. The VHH domain contains the amino acid sequence of SEQ ID NO: 23 or a variant thereof having at least 70% (e.g., at least 75%, 80%, 85%, 90%, 95%, 99%) identity to SEQ ID NO: 23, and the variant substantially retains the binding specificity and / or affinity for serum albumin. Preferably, the variant of SEQ ID NO: 23 has at most 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations in relation to SEQ ID NO: 23, the polypeptide according to claim 1.

11. The polypeptide according to claim 1, wherein the nanobody domain further comprises an N-terminal extension attached to the N-terminus of the VHH domain, and optionally, the N-terminal extension comprises an amino acid residue of SG, AG, S, or A.

12. The polypeptide according to claim 11, wherein the nanobody domain comprises an amino acid sequence selected from SEQ ID NOs: 24 to 27.

13. wherein the first repeat sequence is G ｆ S ｇ , an amino acid sequence selected from the group consisting of SEQ ID NO: 35 (GAQP), SEQ ID NO: 36 (GQAP), SEQ ID NO: 37 (GPAQ), SEQ ID NO: 38 (GPQA), SEQ ID NO: 39 (GSQP), SEQ ID NO: 40 (GASP), SEQ ID NO: 41 (GPAS), SEQ ID NO: 42 (GPSA), SEQ ID NO: 43 (GGGS), SEQ ID NO: 44 (GSGS), SEQ ID NO: 45 (GGGGGS), SEQ ID NO: 46 (GSAPGS PAGSPTGSPAGSP A), and GS, wherein each of f and g is independently an integer selected from 1 to 5, optionally, the first repeat sequence has the amino acid sequence set forth in SEQ ID NO: 35 (GAQP), and the number of said one or more units is an integer from 1 to 10, the polypeptide according to claim 12.

14. The first linker includes an amino acid sequence selected from the group consisting of SEQ ID NO: 35 (GAQP), SEQ ID NO: 49 ((GAQP) ２ ), SEQ ID NO: 50 ((GAQP) ５ ), SEQ ID NO: 51 ((GAQP) １０ ), and SEQ ID NO: 48 (GGGGSGGSG); the polypeptide according to claim 13.

15. Further comprising a third fragment comprising a biologically active protein of glucagon-like peptide-1 (GLP-1) or a fragment thereof beyond the N-terminus of the first fragment, The polypeptide according to claim 1, wherein the first fragment and the third fragment are connected via a second linker.

16. The polypeptide according to claim 15, wherein the biologically active protein of GLP-1 or a fragment thereof comprises one or more mutations in A8G, G22E, K26R, K34R, R36G, or any combination thereof in relation to GLP-1(7-37) whose sequence is represented by SEQ ID NO:

28.

17. The polypeptide according to claim 16, wherein the biologically active protein of GLP-1 or a fragment thereof comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 29 and SEQ ID NOs: 31 to 34.

18. The polypeptide according to claim 17, wherein the second linker has a length of at least 8 amino acid residues.

19. The polypeptide according to claim 1, comprising an amino acid sequence selected from SEQ ID NOs: 63 to 68, 70, 74, 75, 79 to 83, 85, 93 to 101, and 107 to 109.

20. A pharmaceutical composition comprising the polypeptide according to any one of claims 1 to 19 and a pharmaceutically acceptable carrier.

21. The pharmaceutical composition according to claim 20, for use in a method of preventing or treating a metabolic disorder in a subject in need thereof, the method comprising administering a therapeutically effective amount of the polypeptide according to any one of claims 1 to 19.

22. The pharmaceutical composition according to claim 21, wherein the metabolic disorder is diabetes, obesity, non-alcoholic steatohepatitis (NASH), cardiovascular lipid abnormalities, atherosclerosis, alcoholic steatohepatitis (ASH), diabetic nephropathy, gestational diabetes, metabolic syndrome X or other metabolic syndromes, non-alcoholic fatty liver disease (NAFLD), end-stage liver disease, hepatic steatosis (fatty liver), cirrhosis, primary biliary cirrhosis (PBC), or severe hypertriglyceridemia (SHTG).

23. A polynucleotide encoding the polypeptide defined in any one of claims 1 to 19.

24. A vector comprising the polynucleotide according to claim 23.

25. A host cell comprising the vector according to claim 24.

Images